Barry Joel Maron

Q: What Schools Are Affiliated With Barry Joel Maron

Barry Joel Maron is affiliated with the following schools: Kagoshima University, University of Iceland, Baylor College of Medicine, Sapienza University of Rome

Barry Joel Maron's AcademicInfluence.com Rankings

Barry Joel Maron

Medical

#245

World Rank

#364

Historical Rank

Cardiology

World Rank

Historical Rank

medical Degrees

Download Badge

Medical

Barry Joel Maron's Degrees

Doctorate Medicine University of Minnesota

Why Is Barry Joel Maron Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Barry Joel Maron's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interd (2006) (2840)
Hypertrophic cardiomyopathy: a systematic review. (2002) (2239)
Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. (1995) (1783)
Sudden death in young competitive athletes. Clinical, demographic, and pathological profiles. (1996) (1692)
Congenital heart disease caused by mutations in the transcription factor NKX2-5. (1998) (1306)
American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice G (2003) (1303)
2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: Executive Summary A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines (2011) (1257)
Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. (2003) (1200)
Sudden Deaths in Young Competitive Athletes: Analysis of 1866 Deaths in the United States, 1980–2006 (2009) (1144)
Clinical profile of congenital coronary artery anomalies with origin from the wrong aortic sinus leading to sudden death in young competitive athletes. (2000) (1140)
Acute and Reversible Cardiomyopathy Provoked by Stress in Women From the United States (2005) (1057)
2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, American Soci (2011) (1054)
Recommendations and Considerations Related to Preparticipation Screening for Cardiovascular Abnormalities in Competitive Athletes: 2007 Update: A Scientific Statement From the American Heart Association Council on Nutrition, Physical Activity, and Metabolism Endorsed by the American College of Cardi (2007) (1011)
Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. (2000) (1010)
Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. (2000) (964)
Task Force on Sudden Cardiac Death of the European Society of Cardiology. (2001) (929)
The upper limit of physiologic cardiac hypertrophy in highly trained elite athletes. (1991) (906)
2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines (2011) (904)
Exercise and acute cardiovascular events placing the risks into perspective: a scientific statement from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism and the Council on Clinical Cardiology. (2007) (893)
2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. (2011) (889)
Natural history and expansive clinical profile of stress (tako-tsubo) cardiomyopathy. (2010) (784)
New perspectives on the prevalence of hypertrophic cardiomyopathy. (2015) (775)
Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy. (1998) (762)
Comparative left ventricular dimensions in trained athletes. (1975) (758)
Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population. (2000) (758)
Impact of Atrial Fibrillation on the Clinical Course of Hypertrophic Cardiomyopathy (2001) (712)
Intramural ("small vessel") coronary artery disease in hypertrophic cardiomyopathy. (1986) (709)
Prognostic Value of Quantitative Contrast-Enhanced Cardiovascular Magnetic Resonance for the Evaluation of Sudden Death Risk in Patients With Hypertrophic Cardiomyopathy (2014) (698)
The heart of trained athletes: cardiac remodeling and the risks of sports, including sudden death. (2006) (689)
Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. (2005) (662)
Recommendations for interpretation of 12-lead electrocardiogram in the athlete. (2009) (648)
Hypertrophic Cardiomyopathy Is Predominantly a Disease of Left Ventricular Outflow Tract Obstruction (2006) (648)
Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. (2008) (646)
Patterns and significance of distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy. A wide angle, two dimensional echocardiographic study of 125 patients. (1981) (630)
Phenotypic spectrum and patterns of left ventricular hypertrophy in hypertrophic cardiomyopathy: morphologic observations and significance as assessed by two-dimensional echocardiography in 600 patients. (1995) (626)
Genetics of hypertrophic cardiomyopathy after 20 years: clinical perspectives. (2012) (626)
Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. (2007) (607)
Mutations in the cardiac myosin binding protein–C gene on chromosome 11 cause familial hypertrophic cardiomyopathy (1995) (599)
Prevalence, Clinical Profile, and Significance of Left Ventricular Remodeling in the End-Stage Phase of Hypertrophic Cardiomyopathy (2006) (593)
American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice G (2003) (593)
Sudden Death in Young Athletes (1980) (588)
Cardiovascular preparticipation screening of competitive athletes. A statement for health professionals from the Sudden Death Committee (clinical cardiology) and Congenital Cardiac Defects Committee (cardiovascular disease in the young), American Heart Association. (1996) (583)
Glycogen storage diseases presenting as hypertrophic cardiomyopathy. (2005) (575)
Recommendations for physical activity and recreational sports participation for young patients with genetic cardiovascular diseases. (2004) (567)
Clinical course of hypertrophic cardiomyopathy in a regional United States cohort. (1999) (532)
Utility of Cardiac Magnetic Resonance Imaging in the Diagnosis of Hypertrophic Cardiomyopathy (2005) (530)
Structural features of the athlete heart as defined by echocardiography. (1986) (529)
Hypertrophic cardiomyopathy: present and future, with translation into contemporary cardiovascular medicine. (2014) (528)
Causes of sudden death in competitive athletes. (1986) (526)
Clinical significance of abnormal electrocardiographic patterns in trained athletes. (2000) (522)
Sudden death in hypertrophic cardiomyopathy: a profile of 78 patients. (1982) (512)
Introduction: eligibility recommendations for competitive athletes with cardiovascular abnormalities-general considerations. (2005) (485)
Management of hypertrophic cardiomyopathy. (2022) (475)
Assessment of permanent dual-chamber pacing as a treatment for drug-refractory symptomatic patients with obstructive hypertrophic cardiomyopathy. A randomized, double-blind, crossover study (M-PATHY). (1999) (473)
Myocardial ischemia in patients with hypertrophic cardiomyopathy: contribution of inadequate vasodilator reserve and elevated left ventricular filling pressures. (1985) (463)
Hypertrophic cardiomyopathy: a discussion of nomenclature. (1979) (461)
Prognostic significance of 24 hour ambulatory electrocardiographic monitoring in patients with hypertrophic cardiomyopathy: a prospective study. (1981) (454)
Sudden death in young athletes. (1980) (451)
Angina due to coronary microvascular disease in hypertensive patients without left ventricular hypertrophy. (1988) (448)
Serial Long‐term Assessment of the Natural History of Asymptomatic Patients With Chronic Aortic Regurgitation and Normal Left Ventricular Systolic Function (1991) (444)
Noninvasive assessment of left ventricular diastolic function: comparative analysis of Doppler echocardiographic and radionuclide angiographic techniques. (1986) (440)
Prevalence of sudden cardiac death during competitive sports activities in Minnesota high school athletes. (1998) (435)
Clinical Course and Management of Hypertrophic Cardiomyopathy (2018) (415)
Morphology of the "athlete's heart" assessed by echocardiography in 947 elite athletes representing 27 sports. (1994) (415)
Hypertrophic cardiomyopathy. Interrelations of clinical manifestations, pathophysiology, and therapy (1). (1987) (410)
Cardiac disease in young trained athletes. Insights into methods for distinguishing athlete's heart from structural heart disease, with particular emphasis on hypertrophic cardiomyopathy. (1995) (406)
Effects of Verapamil on Left Ventricular Systolic Function and Diastolic Filling in Patients with Hypertrophic Cardiomyopathy (1981) (404)
Hypertrophic cardiomyopathy phenotype revisited after 50 years with cardiovascular magnetic resonance. (2009) (404)
Assessment of Diastolic Function With Doppler Tissue Imaging to Predict Genotype in Preclinical Hypertrophic Cardiomyopathy (2002) (392)
Prevalence, Clinical Significance, and Natural History of Left Ventricular Apical Aneurysms in Hypertrophic Cardiomyopathy (2008) (390)
Noninvasive assessment of left ventricular diastolic function by pulsed Doppler echocardiography in patients with hypertrophic cardiomyopathy. (1987) (387)
Hypertrophic cardiomyopathy and transmural myocardial infarction without significant atherosclerosis of the extramural coronary arteries. (1979) (382)
Morphology and significance of the left ventricular collagen network in young patients with hypertrophic cardiomyopathy and sudden cardiac death. (2000) (382)
Sarcomere Protein Gene Mutations in Hypertrophic Cardiomyopathy of the Elderly (2002) (380)
Prevalence and clinical significance of left atrial remodeling in competitive athletes. (2005) (369)
Expert consensus document American College of Cardiology / European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy (2003) (367)
An experimental model of sudden death due to low-energy chest-wall impact (commotio cordis) (1998) (356)
Hypertrophic cardiomyopathy (2013) (356)
Quantitative Analysis of Cardiac Muscle Cell Disorganization in the Ventricular Septum of Patients with Hypertrophic Cardiomyopathy (1979) (353)
Athlete's heart in women. Echocardiographic characterization of highly trained elite female athletes. (1996) (347)
Remodeling of Left Ventricular Hypertrophy in Elite Athletes After Long-Term Deconditioning (2002) (347)
Blunt impact to the chest leading to sudden death from cardiac arrest during sports activities. (1995) (343)
Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy. (2002) (337)
Mitral valve abnormalities identified by cardiovascular magnetic resonance represent a primary phenotypic expression of hypertrophic cardiomyopathy (2010) (331)
Clinical profile and spectrum of commotio cordis. (2002) (324)
Development and progression of left ventricular hypertrophy in children with hypertrophic cardiomyopathy. (1986) (323)
Diversity of Structural Mitral Valve Alterations in Hypertrophic Cardiomyopathy (1992) (323)
American Heart Association/American College of Cardiology Foundation/Heart Rhythm Society Scientific Statement on Noninvasive Risk Stratification Techniques for Identifying Patients at Risk for Sudden Cardiac Death. A scientific statement from the American Heart Association Council on Clinical Cardi (2008) (321)
Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy. (2005) (314)
Relationship of race to sudden cardiac death in competitive athletes with hypertrophic cardiomyopathy. (2003) (306)
Bethesda Conference #36 and the European Society of Cardiology Consensus Recommendations revisited a comparison of U.S. and European criteria for eligibility and disqualification of competitive athletes with cardiovascular abnormalities. (2008) (298)
Syncope and Risk of Sudden Death in Hypertrophic Cardiomyopathy (2009) (296)
Physiologic limits of left ventricular hypertrophy in elite junior athletes: relevance to differential diagnosis of athlete's heart and hypertrophic cardiomyopathy. (2002) (294)
Occurrence and significance of progressive left ventricular wall thinning and relative cavity dilatation in hypertrophic cardiomyopathy. (1987) (292)
Hypertrophic cardiomyopathy in Tuscany: clinical course and outcome in an unselected regional population. (1995) (292)
Gender-related differences in the clinical presentation and outcome of hypertrophic cardiomyopathy. (2005) (291)
Myocardial perfusion abnormalities in patients with hypertrophic cardiomyopathy: assessment with thallium-201 emission computed tomography. (1987) (287)
26th Bethesda Conferance: Recommendations for determining eligibility for competetion in athletes with cardiovascular abnormalities (1994) (286)
Clinical Profile and Significance of Delayed Enhancement in Hypertrophic Cardiomyopathy (2008) (285)
Outcomes in athletes with marked ECG repolarization abnormalities. (2008) (282)
Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 3: Hypertrophic Cardiomyopathy, Arrhythmogenic Right Ventricular Cardiomyopathy and Other Cardiomyopathies, and Myocarditis: A Scientific Statement From the American Heart Associat (2015) (281)
Echocardiographic assessment of spontaneously occurring feline hypertrophic cardiomyopathy. An animal model of human disease. (1995) (279)
Assessment of the 12-lead ECG as a screening test for detection of cardiovascular disease in healthy general populations of young people (12-25 Years of Age): a scientific statement from the American Heart Association and the American College of Cardiology. (2014) (278)
Long-term clinical significance of frequent and complex ventricular tachyarrhythmias in trained athletes. (2002) (276)
Prognosis of Surgically Corrected Coarctation of the Aorta: A 20‐Year Postoperative Appraisal (1973) (273)
Verapamil-induced improvement in left ventricular diastolic filling and increased exercise tolerance in patients with hypertrophic cardiomyopathy: short- and long-term effects. (1985) (272)
Sexual activity and cardiovascular disease: a scientific statement from the American Heart Association. (2012) (265)
Contemporary insights and strategies for risk stratification and prevention of sudden death in hypertrophic cardiomyopathy. (2010) (264)
The case for myocardial ischemia in hypertrophic cardiomyopathy. (2009) (262)
Assessment and significance of left ventricular mass by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. (2008) (259)
Task Force 4: HCM and other cardiomyopathies, mitral valve prolapse, myocarditis, and Marfan syndrome. (2005) (254)
Spectrum and prognostic significance of arrhythmias on ambulatory Holter electrocardiogram in hypertrophic cardiomyopathy. (2005) (253)
Incidence and causes of sudden death in U.S. college athletes. (2014) (253)
Prevalence of arrhythmias during 24-hour electrocardiographic monitoring and exercise testing in patients with obstructive and nonobstructive hypertrophic cardiomyopathy. (1979) (250)
Hypertrophic Cardiomyopathy in Adulthood Associated With Low Cardiovascular Mortality With Contemporary Management Strategies. (2015) (242)
Classification, Epidemiology, and Global Burden of Cardiomyopathies. (2017) (240)
Anomalous Insertion of Papillary Muscle Directly Into Anterior Mitral Leaflet in Hypertrophic Cardiomyopathy: Significance in Producing Left Ventricular Outflow Obstruction (1991) (239)
The management of hypertrophic cardiomyopathy. (1993) (235)
2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. (2011) (233)
The 50-year history, controversy, and clinical implications of left ventricular outflow tract obstruction in hypertrophic cardiomyopathy from idiopathic hypertrophic subaortic stenosis to hypertrophic cardiomyopathy: from idiopathic hypertrophic subaortic stenosis to hypertrophic cardiomyopathy. (2009) (232)
Prognostic value of systemic blood pressure response during exercise in a community-based patient population with hypertrophic cardiomyopathy. (1999) (231)
Arrhythmogenic Right Ventricular Cardiomyopathy Causing Sudden Cardiac Death in Boxer Dogs: A New Animal Model of Human Disease (2004) (231)
Prevention of sudden cardiac death with implantable cardioverter-defibrillators in children and adolescents with hypertrophic cardiomyopathy. (2013) (229)
Influence of aging on Doppler echocardiographic indices of left ventricular diastolic function. (1988) (229)
Preparticipation cardiovascular evaluation of the competitive athlete: perspectives from the 30-year Italian experience. (1995) (228)
Left ventricular hypertrophy and impaired diastolic filling in essential hypertension. Diastolic mechanisms for systolic dysfunction during exercise. (1990) (227)
Hypertrophic cardiomyopathy. Recent observations regarding the specificity of three hallmarks of the disease: asymmetric septal hypertrophy, septal disorganization and systolic anterior motion of the anterior mitral leaflet. (1980) (226)
"Malignant" hypertrophic cardiomyopathy: identification of a subgroup of families with unusually frequent premature death. (1978) (219)
Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy. II. Effects on exercise capacity and symptomatic status. (1979) (219)
Patterns of inheritance in hypertrophic cardiomyopathy: assessment by M-mode and two-dimensional echocardiography. (1984) (219)
Comparison of surgical septal myectomy and alcohol septal ablation with cardiac magnetic resonance imaging in patients with hypertrophic obstructive cardiomyopathy. (2007) (218)
Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy. I. Hemodynamic effects. (1979) (217)
Development of left ventricular hypertrophy in adults in hypertrophic cardiomyopathy caused by cardiac myosin-binding protein C gene mutations. (2001) (215)
Ultrastructural features of degenerated cardiac muscle cells in patients with cardiac hypertrophy. (1975) (215)
Atrial systole and left ventricular filling in hypertrophic cardiomyopathy: effect of verapamil. (1983) (214)
Quantitative Analysis of the Distribution of Cardiac Muscle Cell Disorganization in the Left Ventricular Wall of Patients with Hypertrophic Cardiomyopathy (1981) (213)
Prognostic significance of left atrial size in patients with hypertrophic cardiomyopathy (from the Italian Registry for Hypertrophic Cardiomyopathy). (2006) (209)
Sudden death in patients with hypertrophic cardiomyopathy: characterization of 26 patients with functional limitation. (1978) (209)
Long-term serial changes in left ventricular function and reversal of ventricular dilatation after valve replacement for chronic aortic regurgitation. (1988) (208)
Comparison of U.S. and Italian experiences with sudden cardiac deaths in young competitive athletes and implications for preparticipation screening strategies. (2009) (207)
Hypertrophic Cardiomyopathy With Left Ventricular Apical Aneurysm: Implications for Risk Stratification and Management. (2017) (206)
Gene Mutations in Apical Hypertrophic Cardiomyopathy (2005) (204)
Long-Term Clinical Course and Symptomatic Status of Patients after Operation for Hypertrophic Subaortic Stenosis (1978) (201)
Etiology of clinically isolated, severe, chronic, pure mitral regurgitation: analysis of 97 patients over 30 years of age having mitral valve replacement. (1982) (201)
Evidence for efficacy of the Italian national pre-participation screening programme for identification of hypertrophic cardiomyopathy in competitive athletes. (2006) (200)
Hypertrophic Cardiomyopathy in Infants: Clinical Features and Natural History (1982) (200)
Demographics and Epidemiology of Sudden Deaths in Young Competitive Athletes: From the United States National Registry. (2016) (199)
The natural history of asymptomatic patients with aortic regurgitation and normal left ventricular function. (1983) (198)
2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. (2011) (197)
Survival and functional results after valve replacement for aortic regurgitation from 1976 to 1983: impact of preoperative left ventricular function. (1985) (196)
Electrophysiologic abnormalities in patients with hypertrophic cardiomyopathy. A consecutive analysis in 155 patients. (1989) (195)
Electrocardiographic Findings in Patients with Obstructive and Nonobstructive Hypertrophic Cardiomyopathy (1978) (194)
Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 3: Hypertrophic Cardiomyopathy, Arrhythmogenic Right Ventricular Cardiomyopathy and Other Cardiomyopathies, and Myocarditis: A Scientific Statement From the American Heart Associat (2015) (194)
Proposal for contemporary screening strategies in families with hypertrophic cardiomyopathy. (2004) (193)
Task Force 1: preparticipation screening and diagnosis of cardiovascular disease in athletes. (2005) (193)
The case for surgery in obstructive hypertrophic cardiomyopathy. (2004) (193)
Reduction in left ventricular wall thickness after deconditioning in highly trained Olympic athletes. (1993) (190)
Clinical course of hypertrophic cardiomyopathy with survival to advanced age. (2003) (189)
Clinical outcome and phenotypic expression in LAMP2 cardiomyopathy. (2009) (188)
Asymmetric Septal Hypertrophy (1974) (186)
Clinicopathological profiles of progressive heart failure in hypertrophic cardiomyopathy (2010) (185)
Results of screening a large group of intercollegiate competitive athletes for cardiovascular disease. (1987) (184)
Task Force on Sudden Cardiac Death, European Society of Cardiology. (2002) (184)
Distinguishing hypertrophic cardiomyopathy from athlete’s heart physiological remodelling: clinical significance, diagnostic strategies and implications for preparticipation screening (2009) (184)
Safety of Sports for Athletes With Implantable Cardioverter-Defibrillators: Results of a Prospective, Multinational Registry (2013) (181)
American Heart Association/american College of Cardiology Foundation/heart Rhythm Society scientific statement on noninvasive risk stratification techniques for identifying patients at risk for sudden cardiac death: a scientific statement from the American Heart Association Council on Clinical Cardi (2008) (181)
Assessment of the 12-lead electrocardiogram as a screening test for detection of cardiovascular disease in healthy general populations of young people (12-25 years of age): a scientific statement from the American Heart Association and the American College of Cardiology. (2014) (179)
A mutant tropomyosin that causes hypertrophic cardiomyopathy is expressed in vivo and associated with an increased calcium sensitivity. (1998) (175)
Implications of left ventricular remodeling in hypertrophic cardiomyopathy. (1998) (175)
Extended septal myectomy for hypertrophic obstructive cardiomyopathy with anomalous mitral papillary muscles or chordae. (2004) (174)
Enhanced American College of Cardiology/American Heart Association Strategy for Prevention of Sudden Cardiac Death in High-Risk Patients With Hypertrophic Cardiomyopathy. (2019) (174)
Utility of continuous wave Doppler echocardiography in the noninvasive assessment of left ventricular outflow tract pressure gradient in patients with hypertrophic cardiomyopathy. (1992) (173)
Update of the guidelines on sudden cardiac death of the European Society of Cardiology. (2003) (173)
Comparison of prevalence of apical hypertrophic cardiomyopathy in Japan and the United States. (2003) (172)
Hypertrophic cardiomyopathy: an important global disease. (2004) (171)
Relation between extent of left ventricular hypertrophy and occurrence of sudden cardiac death in hypertrophic cardiomyopathy. (1990) (170)
Sudden death in young athletes. Lessons from the Hank Gathers affair. (1993) (169)
Risk Stratification and Outcome of Patients With Hypertrophic Cardiomyopathy ≥60 Years of Age (2013) (167)
Current operative treatment of obstructive hypertrophic cardiomyopathy. (1988) (167)
The paradox of exercise. (2000) (164)
Diastolic abnormalities in patients with hypertrophic cardiomyopathy: relation to magnitude of left ventricular hypertrophy. (1985) (164)
Primary prevention of sudden death as a novel treatment strategy in hypertrophic cardiomyopathy. (2003) (164)
Spectrum and significance of electrocardiographic patterns, troponin levels, and thrombolysis in myocardial infarction frame count in patients with stress (tako-tsubo) cardiomyopathy and comparison to those in patients with ST-elevation anterior wall myocardial infarction. (2008) (164)
Relation of electrocardiographic abnormalities and patterns of left ventricular hypertrophy identified by 2-dimensional echocardiography in patients with hypertrophic cardiomyopathy. (1983) (163)
Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Preamble, Principles, and General Considerations: A Scientific Statement From the American Heart Association and American College of Cardiology. (2015) (162)
Impact of physical deconditioning on ventricular tachyarrhythmias in trained athletes. (2004) (162)
Profile of preparticipation cardiovascular screening for high school athletes. (1998) (160)
Hypertrophic cardiomyopathy with ventricular septal hypertrophy localized to the apical region of the left ventricle (apical hypertrophic cardiomyopathy). (1982) (159)
Safety of Sports for Athletes With Implantable Cardioverter-Defibrillators: Long-Term Results of a Prospective Multinational Registry. (2013) (157)
Spontaneously Occurring Arrhythmogenic Right Ventricular Cardiomyopathy in the Domestic Cat: A New Animal Model Similar to the Human Disease (2000) (157)
Inter-association task force recommendations on emergency preparedness and management of sudden cardiac arrest in high school and college athletic programs: a consensus statement. (2007) (157)
Relation of race to electrocardiographic patterns in elite American football players. (2008) (156)
Usefulness of Doppler echocardiographic assessment of diastolic filling in distinguishing “athlete's heart” from hypertrophic cardiomyopathy (1992) (155)
Effects of aging on asynchronous left ventricular regional function and global ventricular filling in normal human subjects. (1988) (154)
Long-term clinical consequences of intense, uninterrupted endurance training in olympic athletes. (2010) (154)
Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy: III. Effects of long-term administration. (1981) (154)
16th Bethesda Conference: Cardiovascular abnormalities in the athlete: recommendations regarding eligibility for competition. October 3-5, 1984. (1985) (152)
Clinical Profile and Consequences of Atrial Fibrillation in Hypertrophic Cardiomyopathy (2017) (150)
Echocardiographic Strain Imaging to Assess Early and Late Consequences of Sarcomere Mutations in Hypertrophic Cardiomyopathy (2009) (149)
Prospective echocardiographic screening for coronary artery anomalies in 1,360 elite competitive athletes. (1993) (149)
Surgical Myectomy Remains the Primary Treatment Option for Severely Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy (2007) (147)
Dynamic subaortic obstruction in hypertrophic cardiomyopathy: analysis by pulsed Doppler echocardiography. (1985) (147)
Independent Assessment of the European Society of Cardiology Sudden Death Risk Model for Hypertrophic Cardiomyopathy. (2015) (146)
Differences in coronary flow and myocardial metabolism at rest and during pacing between patients with obstructive and patients with nonobstructive hypertrophic cardiomyopathy. (1987) (146)
How Hypertrophic Cardiomyopathy Became a Contemporary Treatable Genetic Disease With Low Mortality: Shaped by 50 Years of Clinical Research and Practice. (2016) (146)
Spectrum and clinical significance of systolic function and myocardial fibrosis assessed by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. (2010) (146)
Verapamil prevents silent myocardial perfusion abnormalities during exercise in asymptomatic patients with hypertrophic cardiomyopathy. (1989) (145)
Double or compound sarcomere mutations in hypertrophic cardiomyopathy: a potential link to sudden death in the absence of conventional risk factors. (2012) (145)
Prevalence and Clinical Profile of Myocardial Crypts in Hypertrophic Cardiomyopathy (2011) (140)
Clinical features of hypertrophic cardiomyopathy caused by mutation of a "hot spot" in the alpha-tropomyosin gene. (1997) (139)
Long-term outcome of patients with hypertrophic cardiomyopathy successfully resuscitated after cardiac arrest. (1989) (139)
Myocardial ultrastructure in patients with chronic aortic valve disease. (1975) (136)
Sudden death and the competitive athlete: perspectives on preparticipation screening studies. (1986) (135)
Potential Role of QT Interval Prolongation in Sudden Infant Death Syndrome (1976) (135)
Surgical myectomy versus alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Will there ever be a randomized trial? (2007) (135)
Regional left ventricular asynchrony and impaired global left ventricular filling in hypertrophic cardiomyopathy: effect of verapamil. (1987) (134)
Prognostic value of non-sustained ventricular tachycardia and the potential role of amiodarone treatment in hypertrophic cardiomyopathy: assessment in an unselected non-referral based patient population (1998) (133)
Significance of papillary muscle abnormalities identified by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. (2008) (133)
Effects of verapamil on left ventricular systolic and diastolic function in patients with hypertrophic cardiomyopathy: pressure-volume analysis with a nonimaging scintillation probe. (1983) (132)
Myocardial bridging, a frequent component of the hypertrophic cardiomyopathy phenotype, lacks systematic association with sudden cardiac death. (2009) (132)
Contemporary Natural History and Management of Nonobstructive Hypertrophic Cardiomyopathy. (2016) (132)
Impact directly over the cardiac silhouette is necessary to produce ventricular fibrillation in an experimental model of commotio cordis. (2001) (131)
Asymmetric Septal Hypertrophy in Childhood (1976) (131)
Relation between extent of left ventricular hypertrophy and diastolic filling abnormalities in hypertrophic cardiomyopathy. (1990) (131)
Initial Results of Combined Anterior Mitral Leaflet Plication and Ventricular Septal Myotomy‐Myectomy for Relief of Left Ventricular Outflow Tract Obstruction in Patients With Hypertrophic Cardiomyopathy (1992) (130)
Reversal of left ventricular dysfunction after aortic valve replacement for chronic aortic regurgitation: influence of duration of preoperative left ventricular dysfunction. (1984) (130)
Morphological Determinants of Echocardiographic Patterns of Mitral Valve Systolic AnteriorMotion in Obstructive Hypertrophic Cardiomyopathy (1993) (128)
Distinguishing hypertrophic cardiomyopathy from athlete’s heart: a clinical problem of increasing magnitude and significance (2005) (128)
Clinical profile of hypertrophic cardiomyopathy identified de novo in rural communities. (1999) (127)
Verapamil therapy: a new approach to pharmacologic treatment of hypertrophic cardiomyopathy. (1980) (126)
Doppler echocardiography for assessing left ventricular diastolic function. (1988) (126)
Low Operative Mortality Achieved With Surgical Septal Myectomy: Role of Dedicated Hypertrophic Cardiomyopathy Centers in the Management of Dynamic Subaortic Obstruction. (2015) (125)
Evidence that pharmacological strategies lack efficacy for the prevention of sudden death in hypertrophic cardiomyopathy (2007) (125)
Impact of patient selection biases on the perception of hypertrophic cardiomyopathy and its natural history. (1993) (125)
Transaortic Chordal Cutting: Mitral Valve Repair for Obstructive Hypertrophic Cardiomyopathy With Mild Septal Hypertrophy. (2015) (124)
Upper and lower limits of vulnerability to sudden arrhythmic death with chest-wall impact (commotio cordis). (2003) (124)
Impact of laboratory molecular diagnosis on contemporary diagnostic criteria for genetically transmitted cardiovascular diseases:hypertrophic cardiomyopathy, long-QT syndrome, and Marfan syndrome. A statement for healthcare professionals from the Councils on Clinical Cardiology, Cardiovascular Disea (1998) (123)
Research priorities in hypertrophic cardiomyopathy: report of a Working Group of the National Heart, Lung, and Blood Institute. (2010) (123)
Usefulness of B-Type Natriuretic Peptide Assay in the Assessment of Symptomatic State in Hypertrophic Cardiomyopathy (2004) (122)
Selective activation of the K(+)(ATP) channel is a mechanism by which sudden death is produced by low-energy chest-wall impact (Commotio cordis). (1999) (122)
Incidence of cardiovascular sudden deaths in Minnesota high school athletes. (2013) (121)
Prevalence and Clinical Significance of Aortic Root Dilation in Highly Trained Competitive Athletes (2010) (119)
Hypertrophic Cardiomyopathy in Children, Adolescents, and Young Adults Associated With Low Cardiovascular Mortality With Contemporary Management Strategies (2016) (119)
Assessment of left ventricular hypertrophy in a trained athlete: differential diagnosis of physiologic athlete's heart from pathologic hypertrophy. (2012) (119)
Systolic anterior motion of the posterior mitral leaflet: a previously unrecognized cause of dynamic subaortic obstruction in patients with hypertrophic cardiomyopathy. (1983) (119)
Preparticipation cardiovascular screening for US collegiate student-athletes. (2000) (118)
Absence of left ventricular wall thickening in athletes engaged in intense power training. (1993) (117)
Preparticipation echocardiographic screening for cardiovascular disease in a large, predominantly black population of collegiate athletes. (1989) (117)
Differentiating left ventricular hypertrophy in athletes from that in patients with hypertrophic cardiomyopathy. (2014) (116)
Pitfalls in clinical recognition and a novel operative approach for hypertrophic cardiomyopathy with severe outflow obstruction due to anomalous papillary muscle. (1998) (116)
Risk for sudden cardiac death associated with marathon running. (1996) (115)
Competitive athletes with cardiovascular disease--the case of Nicholas Knapp. (1998) (114)
Letter by Maron et al Regarding Article, "Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights From the Sarcomeric Human Cardiomyopathy Registry (SHaRe)". (2019) (112)
Relation of electrocardiographic abnormalities to evolving left ventricular hypertrophy in hypertrophic cardiomyopathy during childhood. (1989) (112)
Cardiovascular involvement in osteogenesis imperfecta. (1986) (110)
Familial hypertrophic cardiomyopathy and atrial fibrillation caused by Arg663His beta-cardiac myosin heavy chain mutation. (1999) (110)
Risk of sudden death and outcome in patients with hypertrophic cardiomyopathy with benign presentation and without risk factors. (2014) (110)
The development of the semilunar valves in the human heart. (1974) (109)
Patterns of systolic anterior motion of the mitral valve in hypertrophic cardiomyopathy: assessment by two-dimensional echocardiography. (1984) (108)
Why not just call it tako-tsubo cardiomyopathy: a discussion of nomenclature. (2011) (105)
Significance of Left Ventricular Outflow Tract Cross‐sectional Area in Hypertrophic Cardiomyopathy: A Two‐dimensional Echocardiographic Assessment (1983) (105)
Epidemiology and clinical profile of Takotsubo cardiomyopathy. (2014) (104)
Prevalence of hypertrophic cardiomyopathy in an outpatient population referred for echocardiographic study. (1994) (104)
Evidence for decreasing occurrence of sudden cardiac death associated with the marathon. (2005) (103)
Comparison of morphologic findings in spontaneously occurring hypertrophic cardiomyopathy in humans, cats and dogs. (1993) (103)
Hypertrophic cardiomyopathy and other causes of sudden cardiac death in young competitive athletes, with considerations for preparticipation screening and criteria for disqualification. (2007) (102)
Elderly patients with hypertrophic cardiomyopathy: a subset with distinctive left ventricular morphology and progressive clinical course late in life. (1989) (102)
Circadian variability in the occurrence of sudden cardiac death in patients with hypertrophic cardiomyopathy. (1994) (101)
Obesity and its association to phenotype and clinical course in hypertrophic cardiomyopathy. (2013) (100)
Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 2: Preparticipation Screening for Cardiovascular Disease in Competitive Athletes: A Scientific Statement From the American Heart Association and American College of Cardiology. (2015) (100)
Heterogeneous Morphologic Expression of Genetically Transmitted Hypertrophic Cardiomyopathy: Two–dimensional Echocardiographic Analysis (1983) (99)
Severe functional limitation in patients with hypertrophic cardiomyopathy and only mild localized left ventricular hypertrophy. (1986) (99)
Task force 3: Hypertrophic cardiomyopathy, myocarditis and other myopericardial diseases and mitral valve prolapse (1994) (99)
Report of the NASPE Policy Conference on Arrhythmias and the Athlete (2001) (98)
Effect of surgical reduction of left ventricular outflow obstruction on hemodynamics, coronary flow, and myocardial metabolism in hypertrophic cardiomyopathy. (1989) (98)
Quantitative Analysis of Cardiac Muscle Cell Disorganization in the Ventricular Septum: Comparison of Fetuses and Infants with and Without Congenital Heart Disease and Patients with Hypertrophic Cardiomyopathy (1979) (98)
Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 10: The Cardiac Channelopathies: A Scientific Statement From the American Heart Association and American College of Cardiology. (2015) (97)
Apical hypertrophic cardiomyopathy: clinical and two-dimensional echocardiographic assessment. (1987) (97)
Clinical Profile of Commotio Cordis: An Under Appreciated Cause of Sudden Death in the Young During Sports and Other Activities (1999) (97)
Controversies in cardiovascular medicine. Surgical myectomy remains the primary treatment option for severely symptomatic patients with obstructive hypertrophic cardiomyopathy. (2007) (96)
Moving Beyond the Sarcomere to Explain Heterogeneity in Hypertrophic Cardiomyopathy: JACC Review Topic of the Week. (2019) (96)
Symptomatic status and prognosis of patients after operation for hypertrophic obstructive cardiomyopathy: efficacy of ventricular septal myotomy and myectomy. (1983) (96)
Absence of progression of left ventricular hypertrophy in adult patients with hypertrophic cardiomyopathy. (1987) (96)
Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Preamble, Principles, and General Considerations: A Scientific Statement From the American Heart Association and American College of Cardiology. (2015) (96)
Prevalence and Characteristics of Disproportionate Ventricular Septal Thickening in Patients with Acquired or Congenital Heart Diseases: Echocardiographic and Morphologic Findings (1977) (95)
Lessons From the Failure and Recall of an Implantable Cardioverter-Defibrillator (2005) (95)
Isovolumic relaxation period in hypertrophic cardiomyopathy: assessment by radionuclide angiography. (1986) (94)
Hypertrophic cardiomyopathy – Authors' reply (2013) (94)
Clinical Spectrum and Management of Heart Failure in Hypertrophic Cardiomyopathy. (2018) (94)
Clinical challenges of genotype positive (+)-phenotype negative (-) family members in hypertrophic cardiomyopathy. (2011) (94)
Cardiac norepinephrine kinetics in hypertrophic cardiomyopathy. (1989) (93)
Significance of false negative electrocardiograms in preparticipation screening of athletes for hypertrophic cardiomyopathy. (2012) (93)
Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 7: Aortic Diseases, Including Marfan Syndrome: A Scientific Statement From the American Heart Association and American College of Cardiology. (2015) (93)
Sudden death during the triathlon. (2010) (92)
Sudden cardiac death in the young (2002) (92)
Left atrial remodeling in hypertrophic cardiomyopathy and susceptibility markers for atrial fibrillation identified by cardiovascular magnetic resonance. (2014) (91)
Reduced risk of sudden death from chest wall blows (commotio cordis) with safety baseballs. (2002) (90)
Implantable Defibrillators and Prevention of Sudden Death in Hypertrophic Cardiomyopathy (2008) (89)
Outer limits of the athlete's heart, the effect of gender, and relevance to the differential diagnosis with primary cardiac diseases. (1997) (88)
Controversies in cardiovascular medicine. Benefits of surgery in obstructive hypertrophic cardiomyopathy: bring septal myectomy back for European patients. (2011) (88)
Revised eligibility recommendations for competitive athletes with cardiovascular abnormalities. (1994) (87)
Differences in distribution of myocardial abnormalities in patients with obstructive and nonobstructive asymmetric septal hypertrophy (ASH). Light and electron microscopic findings. (1974) (87)
Hypertrophic Cardiomyopathy with Unusual Locations of Left Ventricular Hypertrophy Undetectable, by M‐mode Echocardiography: Identification by Wide‐angle Two‐dimensional Echocardiography (1981) (87)
Epidemiology of Sudden Death in Young, Competitive Athletes Due to Blunt Trauma (2011) (86)
Hypertrophic cardiomyopathy: quantification of late gadolinium enhancement with contrast-enhanced cardiovascular MR imaging. (2011) (85)
Commotio Cordis—Sudden Cardiac Death with Chest Wall Impact (2007) (85)
Hypertrophic cardiomyopathy with extreme increase in left ventricular wall thickness: functional and morphologic features and clinical significance. (1986) (84)
Tunnel Subaortic Stenosis: Left Ventricular Outflow Tract Obstruction Produced by Fibromuscular Tubular Narrowing (1976) (84)
Failure of Commercially Available Chest Wall Protectors to Prevent Sudden Cardiac Death Induced by Chest Wall Blows in an Experimental Model of Commotio Cordis (2006) (83)
Role of family history of sudden death in risk stratification and prevention of sudden death with implantable defibrillators in hypertrophic cardiomyopathy. (2010) (82)
Two‐dimensional Echocardiographic Assessment of the Idiopathic Hypereosinophilic Syndrome: Anatomic Basis of Mitral Regurgitation and Peripheral Embolization (1983) (82)
Sudden cardiac arrest in hypertrophic cardiomyopathy in the absence of conventional criteria for high risk status. (2008) (82)
Clinical and hemodynamic results after mitral valve replacement in patients with obstructive hypertrophic cardiomyopathy. (1989) (81)
Feline hypertrophic cardiomyopathy: gross anatomic and quantitative histologic features. (1981) (80)
Left Ventricular Outflow Tract Obstruction Due to Systolic Anterior Motion of the Anterior Mitral Leaflet in Patients with Concentric Left Ventricular Hypertrophy (1978) (79)
Relation of electrocardiographic patterns to phenotypic expression and clinical outcome in hypertrophic cardiomyopathy. (2005) (79)
Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 2: Preparticipation Screening for Cardiovascular Disease in Competitive Athletes: A Scientific Statement From the American Heart Association and American College of Cardiology. (2015) (79)
Asymmetric Septal Hypertrophy (ASH) in Infancy (1974) (79)
Prevalence of hypertrophic cardiomyopathy in a population-based sample of American Indians aged 51 to 77 years (the Strong Heart Study). (2004) (79)
Sudden cardiac death in hypertrophic cardiomyopathy. (1992) (78)
Coexistence of sudden cardiac death and end-stage heart failure in familial hypertrophic cardiomyopathy. (1993) (77)
Disproportionate Ventricular Septal Thickening in Patients with Systemic Hypertension (1978) (77)
[Task Force on Sudden Cardiac Death, European Society of Cardiology. Summary of recommendations]. (2002) (77)
Comparison of Echocardiographic and Necropsy Measurements of Ventricular Wall Thicknesses in Patients with and without Disproportionate Septal Thickening (1977) (76)
Adrenergic receptor polymorphisms in patients with stress (tako-tsubo) cardiomyopathy. (2009) (76)
Cardioverter-defibrillator implantation in high-risk patients with hypertrophic cardiomyopathy. (2005) (76)
Systemic and left ventricular responses to exercise stress in asymptomatic patients with valvular aortic stenosis. (1991) (75)
Clinicopathologic features of hypertrophic cardiomyopathy managed by cardiac transplantation. (1993) (75)
Significance of sarcomere gene mutations analysis in the end-stage phase of hypertrophic cardiomyopathy. (2014) (74)
Risk stratification and role of implantable defibrillators for prevention of sudden death in patients with hypertrophic cardiomyopathy. (2010) (74)
Role of Percutaneous Septal Ablation in Hypertrophic Obstructive Cardiomyopathy (2004) (74)
Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 10: The Cardiac Channelopathies: A Scientific Statement From the American Heart Association and American College of Cardiology. (2015) (74)
Electrocardiographic features of sarcomere mutation carriers with and without clinically overt hypertrophic cardiomyopathy. (2011) (74)
Use of calcium-channel blocking drugs in hypertrophic cardiomyopathy. (1985) (73)
The Electrocardiogram as a Diagnostic Tool for Hypertrophic Cardiomyopathy: Revisited (2001) (73)
Inducible polymorphic ventricular tachycardia and ventricular fibrillation in a subgroup of patients with hypertrophic cardiomyopathy at high risk for sudden death. (1987) (73)
Clinical significance and therapeutic implications of the left ventricular outflow tract pressure gradient in hypertrophic cardiomyopathy. (1986) (73)
Role of alcohol septal ablation in treatment of obstructive hypertrophic cardiomyopathy (2000) (73)
Hypertrophic cardiomyopathy. Interrelations of clinical manifestations, pathophysiology, and therapy (2). (1987) (71)
Echocardiographic Assessment of Mitral Valve Size in Obstructive Hypertrophic Cardiomyopathy Anatomic Validation From Mitral Valve Specimen (1993) (71)
Disproportionate Ventricular Septal Thickening in the Developing Normal Human Heart (1978) (70)
How should we screen competitive athletes for cardiovascular disease? (2005) (70)
Sudden death in hypertrophic cardiomyopathy with normal left ventricular mass. (1990) (69)
Reproducibility of Doppler echocardiographic measurements of left ventricular diastolic function. (1988) (69)
26th Bethesda conference: recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities. Task Force 3: hypertrophic cardiomyopathy, myocarditis and other myopericardial diseases and mitral valve prolapse. (1994) (68)
Relation between extent of cardiac muscle cell disorganization and left ventricular wall thickness in hypertrophic cardiomyopathy. (1992) (68)
Surgical Septal Myectomy Versus Alcohol Septal Ablation: Assessing the Status of the Controversy in 2014 (2014) (68)
Evolution in the process of screening United States high school student-athletes for cardiovascular disease. (2007) (67)
Management implications of massive left ventricular hypertrophy in hypertrophic cardiomyopathy significantly underestimated by echocardiography but identified by cardiovascular magnetic resonance. (2010) (67)
Morphologic determinants of hemodynamic state after ventricular septal myotomy-myectomy in patients with obstructive hypertrophic cardiomyopathy: M mode and two-dimensional echocardiographic assessment. (1984) (67)
Electrophysiologic Manifestations of Ventricular Tachyarrhythmias Provoking Appropriate Defibrillator Interventions in High‐Risk Patients with Hypertrophic Cardiomyopathy (2007) (66)
Postoperative Assessment of Patients with Ventricular Septal Defect and Pulmonary Hypertension: Response to Intense Upright Exercise (1973) (65)
Sickle cell trait associated with sudden death in competitive athletes. (2012) (65)
Brief Communication: Cardiovascular Screening Practices of Major North American Professional Sports Teams (2006) (65)
Clinical Impact of Contemporary Cardiovascular Magnetic Resonance Imaging in Hypertrophic Cardiomyopathy (2015) (64)
Human heart and platelet actins are products of different genes. (1976) (64)
Significance of Late Gadolinium Enhancement at Right Ventricular Attachment to Ventricular Septum in Patients With Hypertrophic Cardiomyopathy. (2015) (64)
Increasing survival rate from commotio cordis. (2013) (64)
Relation between extent of left ventricular hypertrophy and age in hypertrophic cardiomyopathy. (1989) (63)
Evaluation of chest barriers for protection against sudden death due to commotio cordis. (2007) (63)
Contemporary strategies for risk stratification and prevention of sudden death with the implantable defibrillator in hypertrophic cardiomyopathy. (2016) (62)
Medical and legal issues in the cardiovascular evaluation of competitive athletes. (2005) (62)
Cardiovascular preparticipation screening of competitive athletes: addendum: an addendum to a statement for health professionals from the Sudden Death Committee (Council on Clinical Cardiology) and the Congenital Cardiac Defects Committee (Council on Cardiovascular Disease in the Young), American He (1998) (62)
Survival following blunt chest impact-induced cardiac arrest during sports activities in young athletes. (1997) (62)
Increased right ventricular wall thickness in left ventricular pressure overload: echocardiographic determination of hypertrophic response of the "nonstressed" ventricle. (1985) (61)
Intermediate-Signal-Intensity Late Gadolinium Enhancement Predicts Ventricular Tachyarrhythmias in Patients With Hypertrophic Cardiomyopathy (2012) (61)
Congenital Heart Malformations Associated with Disproportionate Ventricular Septal Thickening (1975) (61)
Advanced Heart Failure With Preserved Systolic Function in Nonobstructive Hypertrophic Cardiomyopathy: Under-Recognized Subset of Candidates for Heart Transplant (2014) (61)
Differential Diagnosis of Anomalies of the Great Arteries by Real,time Two,dimensional Echocardiography (1975) (61)
Relation of left ventricular thickness to age and gender in hypertrophic cardiomyopathy. (2003) (61)
Results of surgical septal myectomy for obstructive hypertrophic cardiomyopathy: the Tufts experience. (2017) (60)
Nationwide Study on Hypertrophic Cardiomyopathy in Iceland: Evidence of a MYBPC3 Founder Mutation (2014) (60)
Ultrastructural features of hypertrophied human ventricular myocardium. (1978) (60)
Clinical significance of exercise-induced ventricular tachyarrhythmias in trained athletes without cardiovascular abnormalities. (2015) (60)
Long-Term Hemodynamic and Electrocardiographic Assessment Following Operative Repair of Tetralogy of Fallot (1978) (59)
Significance of left ventricular apical-basal muscle bundle identified by cardiovascular magnetic resonance imaging in patients with hypertrophic cardiomyopathy. (2014) (59)
Relation between training-induced left ventricular hypertrophy and risk for ventricular tachyarrhythmias in elite athletes. (2008) (59)
Surviving competitive athletics with hypertrophic cardiomyopathy. (1994) (58)
Cardiology Patient Page. Takotsubo (stress) cardiomyopathy. (2011) (58)
Long-term survival after cardiac arrest in hypertrophic cardiomyopathy. (2009) (58)
Arousal and nonarousal enuretic events. (1969) (57)
Coexistence of mitral valve prolapse in a consecutive group of 528 patients with hypertrophic cardiomyopathy assessed with echocardiography. (1992) (57)
β Blockers for prevention of exercise-induced left ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy. (2012) (57)
The Athlete’s Heart: Remodeling, Electrocardiogram And Preparticipation Screening (2002) (57)
First Experience With Percutaneous Mitral Valve Plication as Primary Therapy for Symptomatic Obstructive Hypertrophic Cardiomyopathy. (2016) (57)
Determinants for clinical diagnosis of hypertrophic cardiomyopathy. (2006) (56)
Noninvasive assessment of left ventricular diastolic function: comparative analysis of pulsed Doppler ultrasound and digitized M-mode echocardiography. (1986) (56)
Patterns of ventricular tachyarrhythmias associated with training, deconditioning and retraining in elite athletes without cardiovascular abnormalities. (2011) (56)
How should hypertrophic cardiomyopathy be classified?: What's in a name? Dilemmas in nomenclature characterizing hypertrophic cardiomyopathy and left ventricular hypertrophy. (2009) (56)
Death and Cardiac Arrest in U.S. Triathlon Participants, 1985 to 2016 (2017) (56)
Inter-association Task Force recommendations on emergency preparedness and management of sudden cardiac arrest in high school and college athletic programs: a consensus statement. (2007) (56)
Screening for hypertrophic cardiomyopathy in a young male military population. (2003) (56)
Circadian patterns in the occurrence of malignant ventricular tachyarrhythmias triggering defibrillator interventions in patients with hypertrophic cardiomyopathy. (2009) (55)
Risk for atrial fibrillation in patients with hypertrophic cardiomyopathy assessed by signal averaged P wave duration. (1997) (55)
Risk factors and stratification for sudden cardiac death in patients with hypertrophic cardiomyopathy. (1994) (55)
Task Force 12: legal aspects of the 36th Bethesda Conference recommendations. (2005) (55)
Development and Determinants of Dynamic Obstruction to Left Ventricular Outflow in Young Patients With Hypertrophic Cardiomyopathy (1992) (54)
Atrioventricular valve replacement in the idiopathic hypereosinophilic syndrome. (1982) (54)
Morphologic basis for obstruction to right ventricular outflow in hypertrophic cardiomyopathy. (1993) (54)
Apical hypertrophic cardiomyopathy: the continuing saga. (1990) (54)
Prevention of Sudden Death in Hypertrophic Cardiomyopathy: But Which Defibrillator for Which Patient? (2004) (54)
Role of Exercise Testing in Hypertrophic Cardiomyopathy. (2017) (53)
Global Burden of Hypertrophic Cardiomyopathy. (2018) (53)
Perspectives on the role of new treatment strategies in hypertrophic obstructive cardiomyopathy. (1999) (53)
Spontaneously occurring restrictive nonhypertrophied cardiomyopathy in domestic cats: a new animal model of human disease. (2014) (53)
Diversity of patterns of hypertrophy in patients with systemic hypertension and marked left ventricular wall thickening. (1990) (53)
Successful Catheter Ablation of Hemodynamically Unstable Monomorphic Ventricular Tachycardia in a Patient with Hypertrophic Cardiomyopathy and Apical Aneurysm (2009) (53)
CMR with late gadolinium enhancement in genotype positive-phenotype negative hypertrophic cardiomyopathy. (2012) (53)
Clinical and morphologic expression of hypertrophic cardiomyopathy in patients > or = 65 years of age. (1994) (52)
Prevalence and characteristics of disproportionate ventricular septal thickening in patients with coronary artery disease. (1978) (52)
Benign clinical significance of J-wave pattern (early repolarization) in highly trained athletes. (2014) (51)
Unusual Evolution of Acquired Infundibular Stenosis in Patients with Ventricular Septal Defect: Clinical and Morphologic Observations (1973) (51)
Severe mitral or aortic valve regurgitation, or both, requiring valve replacement for infective endocarditis complicating hypertrophic cardiomyopathy. (1992) (51)
Triggers for sudden cardiac death in the athlete. (1996) (51)
Outcomes in Patients With Hypertrophic Cardiomyopathy and Left Ventricular Systolic Dysfunction. (2020) (51)
National Electrocardiography Screening for Competitive Athletes: Feasible in the United States? (2010) (51)
Left ventricular diastolic filling abnormalities identified by Doppler echocardiography in asymptomatic patients with sickle cell anemia. (1991) (50)
Right ventricular cardiomyopathy: another cause of sudden death in the young. (1988) (50)
Ability of Prospective Assessment of Personality Profiles to Predict the Practice Specialty of Medical Students (2007) (50)
Diagnosis and Evaluation of Hypertrophic Cardiomyopathy: JACC State-of-the-Art Review. (2022) (50)
Automated External Defibrillator Arrhythmia Detection in a Model of Cardiac Arrest due to Commotio Cordis (2003) (50)
Papillary muscle insertion directly into the anterior mitral leaflet in hypertrophic cardiomyopathy, its identification and cause of outflow obstruction by cardiac magnetic resonance imaging, and its surgical management. (2013) (50)
Prognostic Implications of Nonsustained Ventricular Tachycardia in High-Risk Patients With Hypertrophic Cardiomyopathy (2017) (50)
THE ATHLETE'S HEART SYNDROME: A NEW PERSPECTIVE (1977) (48)
Hypertrophic cardiomyopathy and cardiac muscle cell disorganization revisited: relation between the two and significance. (1981) (48)
Comparison of the Frequency of Sudden Cardiovascular Deaths in Young Competitive Athletes Versus Nonathletes: Should We Really Screen Only Athletes? (2016) (48)
Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 7: Aortic Diseases, Including Marfan Syndrome: A Scientific Statement From the American Heart Association and American College of Cardiology. (2015) (47)
Clinical Profile of Patients With High-Risk Tako-Tsubo Cardiomyopathy. (2015) (47)
Cross-sectional Echocardiography in the Diagnosis of Congenital Heart Disease: Identification of the Relation of the Ventricles and Great Arteries (1977) (46)
Hypertrophic cardiomyopathy in the dog. (1979) (46)
The nuclear membranes in hypertrophied human cardiac muscle cells. (1975) (46)
Relation between extent of left ventricular hypertrophy and occurrence of ventricular tachycardia in hypertrophic cardiomyopathy. (1987) (46)
Evolution of Hypertrophic Cardiomyopathy to a Contemporary Treatable Disease (2012) (45)
Characteristics of the cardiac hypertrophy in Friedreich's ataxia. (1982) (45)
Relation between marked changes in left ventricular outflow tract gradient and disease progression in hypertrophic cardiomyopathy. (1984) (45)
Aggregates of tubules in human cardiac muscle cells. (1974) (45)
The 2006 American Heart Association Classification of Cardiomyopathies Is the Gold Standard (2008) (45)
Cost‐Effectiveness of Implanted Defibrillators in Young People with Inherited Cardiac Arrhythmias (2005) (45)
From malignant mutations to malignant domains: the continuing search for prognostic significance in the mutant genes causing hypertrophic cardiomyopathy (2003) (45)
Implications of hypertrophic cardiomyopathy transmitted by sperm donation. (2009) (44)
Degree of left ventricular hypertrophy in patients with hypertrophic cardiomyopathy and chronic atrial fibrillation. (1992) (44)
Appraisal of dual-chamber pacing therapy in hypertrophic cardiomyopathy: too soon for a rush to judgment? (1996) (44)
Cardiac lymphoma mimicking hypertrophic cardiomyopathy. (1981) (44)
Intracytoplasmic junctions in cardiac muscle cells. (1974) (43)
Global epidemiology and demographics of commotio cordis. (2011) (43)
Emergence of gene mutation carriers and the expanding disease spectrum of hypertrophic cardiomyopathy. (2010) (43)
Clinical Outcome and Phenotypic Expression in LAMP 2 Cardiomyopathy (2009) (43)
Why we need more septal myectomy surgeons: An emerging recognition (2017) (42)
Task Force 11: commotio cordis. (2005) (42)
Significance of multiple intercalated discs in hypertrophied human myocardium. (1973) (41)
Effect of Spironolactone on Myocardial Fibrosis and Other Clinical Variables in Patients with Hypertrophic Cardiomyopathy. (2018) (41)
The congenital long QT syndrome and implications for young athletes. (2006) (41)
Asymmetry in hypertrophic cardiomyopathy: the septal to free wall thickness ratio revisited. (1985) (40)
Role of Streptomycin‐Sensitive Stretch‐Activated Channel in Chest Wall Impact Induced Sudden Death (Commotio Cordis) (2005) (40)
Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy. (1980) (40)
Impact of Sex on Clinical Course and Survival in the Contemporary Treatment Era for Hypertrophic Cardiomyopathy (2019) (40)
How to Image Hypertrophic Cardiomyopathy. (2017) (40)
The Remarkable 50 Years of Imaging in HCM and How it Has Changed Diagnosis and Management: From M-Mode Echocardiography to CMR. (2016) (40)
Prospective identification by two-dimensional echocardiography of anomalous origin of the left main coronary artery from the right sinus of Valsalva. (1991) (40)
What Do Patients With Hypertrophic Cardiomyopathy Die from? (2016) (39)
Cardiovascular consequences of the aging process. (1992) (39)
Commotio Cordis and the Epidemiology of Sudden Death in Competitive Lacrosse (2009) (39)
Effect of Left Ventricular Outflow Tract Obstruction on Left Atrial Mechanics in Hypertrophic Cardiomyopathy (2015) (39)
Assessment of QT dispersion as a prognostic marker for sudden death in a regional nonreferred hypertrophic cardiomyopathy cohort. (2001) (38)
Strategies for assessing the prevalence of cardiovascular sudden deaths in young competitive athletes. (2014) (38)
Transmural myocardial infarction in hypertrophic cardiomyopathy: a cause of conversion from left ventricular asymmetry to symmetry and from normal-sized to dilated left ventricular cavity. (1981) (38)
The young competitive athlete with cardiovascular abnormalities: causes of sudden death, detection by preparticipation screening, and standards for disqualification. (2002) (37)
Surgery for Hypertrophic Obstructive Cardiomyopathy: Alive and Quite Well (2005) (37)
Drug-induced toxic myocarditis. (2003) (37)
Results of operation for coexistent obstructive hypertrophic cardiomyopathy and coronary artery disease. (1989) (36)
Late results of aortic valvotomy for congenital valvar aortic stenosis. (1990) (36)
Timing and significance of exercise-induced left ventricular outflow tract pressure gradients in hypertrophic cardiomyopathy. (2010) (36)
Peculiar focal myocardial degeneration and fatal ventricular arrhythmias in a child. (1972) (36)
Hypertrophic cardiomyopathy in childhood. (2004) (36)
Valvular aortic stenosis and asymmetric septal hypertrophy: diagnostic considerations and clinical and therapeutic implications. (1988) (35)
Results of operation for obstructive hypertrophic cardiomyopathy in the elderly. Septal myotomy and myectomy in 20 patients 65 years of age or older. (1980) (35)
Hypertrophic cardiomyopathy in man and cats. (2015) (35)
Mechanism of Progressive Heart Failure and Significance of Pulmonary Hypertension in Obstructive Hypertrophic Cardiomyopathy (2017) (35)
Hypertrophic cardiomyopathy with left ventricular apical diverticulum. (1996) (35)
Cell Membrane Stretch and Chest Blow‐Induced Ventricular Fibrillation: Commotio Cordis (2008) (35)
Significance of eft Atrial Remodeling in Competitive Athletes (2016) (35)
Death in a young athlete due to commotio cordis despite prompt external defibrillation. (2005) (35)
Unpredictable implantable cardioverter-defibrillator pulse generator failure due to electrical overstress causing sudden death in a young high-risk patient with hypertrophic cardiomyopathy. (2005) (35)
Prevalence and significance of an abnormal S-T segment response to exercise in a young athletic population. (1983) (34)
Spherical microparticles in human myocardium: an ultrastructural study. (1976) (34)
Hypertrophic cardiomyopathy with longevity to 90 years or older. (2012) (34)
Interaction of Adverse Disease Related Pathways in Hypertrophic Cardiomyopathy. (2017) (34)
Clinical Course and Quality of Life in High-Risk Patients With Hypertrophic Cardiomyopathy and Implantable Cardioverter-Defibrillators (2018) (34)
Identification of unexpected nonatherosclerotic cardiovascular disease with coronary CT angiography. (2009) (33)
Contemporary considerations for risk stratification, sudden death and prevention in hypertrophic cardiomyopathy (2003) (33)
Safety and efficacy of transvenous high-voltage implantable cardioverter-defibrillator leads in high-risk hypertrophic cardiomyopathy patients. (2008) (33)
Implications of Arrhythmias and Prevention of Sudden Death in Hypertrophic Cardiomyopathy (2007) (33)
Individualized interactomes for network-based precision medicine in hypertrophic cardiomyopathy with implications for other clinical pathophenotypes (2021) (33)
Novel frameshift mutation in Troponin C (TNNC1) associated with hypertrophic cardiomyopathy and sudden death (2011) (32)
Paradigm of Sudden Death Prevention in Hypertrophic Cardiomyopathy. (2019) (32)
Specificity of systolic anterior motion of anterior mitral leaflet for hypertrophic cardiomyopathy. Prevalence in large population of patients with other cardiac diseases. (1981) (32)
Significance and relation between magnitude of left ventricular hypertrophy and heart failure symptoms in hypertrophic cardiomyopathy. (2005) (32)
Hypertrophic cardiomyopathy and sudden death: new perspectives on risk stratification and prevention with the implantable cardioverter-defibrillator. (2000) (31)
Novel Locus for an Inherited Cardiomyopathy Maps to Chromosome 7 (2006) (31)
Revised eligibility recommendations for competitive athletes with cardiovascular abnormalities. (1994) (31)
Hypertrophic cardiomyopathy centers. (2009) (31)
Impact of Advanced Therapies for Improving Survival to Heart Transplant in Patients with Hypertrophic Cardiomyopathy. (2018) (31)
Ventricular Tachyarrhythmias in Patients With Hypertrophic Cardiomyopathy and Defibrillators: Triggers, Treatment, and Implications (2017) (31)
Hypertrophic cardiomyopathy: a common cause of sudden death in the young competitive athlete. (1983) (31)
Clinical Course and Significance of Hypertrophic Cardiomyopathy Without Left Ventricular Hypertrophy. (2019) (31)
Historical Perspectives on Sudden Deaths in Young Athletes With Evolution over 35 Years. (2015) (31)
Hypertrophic Cardiomyopathy (2002) (31)
Relation of extreme left ventricular hypertrophy to age in hypertrophic cardiomyopathy. (2003) (30)
The genetics of hypertrophic cardiomyopathy. (1986) (30)
Maron Hypertrophic Cardiomyopathy : A Systematic Review (2002) (30)
Hypertrophic cardiomyopathy without hypertrophy: an emerging pre-clinical subgroup composed of genetically affected family members. (2009) (30)
Prolapse of the mitral valve (floppy valve) associated with Ebstein's anomaly of the tricuspid valve (1976) (30)
The Hypertrophic Cardiomyopathy Phenotype Viewed Through the Prism of Multimodality Imaging: Clinical and Etiologic Implications. (2019) (29)
Lack of Phenotypic Differences by Cardiovascular Magnetic Resonance Imaging in MYH7 (&bgr;-Myosin Heavy Chain)- Versus MYBPC3 (Myosin-Binding Protein C)-Related Hypertrophic Cardiomyopathy (2017) (29)
Inter-Association Task Force Recommendations on Emergency Preparedness and Management of Sudden Cardiac Arrest in High School and College Athletic Programs: A Consensus Statement (2007) (29)
The preparticipation physical examination: steps toward consensus and uniformity. (1999) (29)
Counterpoint/Mandatory ECG screening of young competitive athletes. (2012) (29)
Protecting Our Children From the Consequences of Chest Blows on the Playing Field: A Time for Science Over Marketing (2008) (29)
Left ventricular myotomy and myectomy in patients with obstructive hypertrophic cardiomyopathy and previous cardiac arrest. (1980) (28)
Criminal consequences of commotio cordis. (2002) (28)
Task force III: Hypertrophic cardiomyopathy, other myopericardial diseases and mitral valve prolapse (1985) (27)
Identification of Congenital Malformations of the Great Arteries in Infants by Real‐time Two‐dimensional Echocardiography (1975) (27)
Clinical significance of atrial fibrillation in hypertrophic cardiomyopathy (2001) (27)
Guideline-Based Referral for Septal Reduction Therapy in Obstructive Hypertrophic Cardiomyopathy Is Associated With Excellent Clinical Outcomes. (2019) (27)
Identification of Fabry Disease in a Tertiary Referral Cohort of Patients with Hypertrophic Cardiomyopathy. (2017) (27)
PROGNOSTIC UTILITY OF CONTRAST-ENHANCED CARDIOVASCULAR MAGNETIC RESONANCE IN HYPERTROPHIC CARDIOMYOPATHY: AN INTERNATIONAL MULTICENTER STUDY (2012) (27)
Occurrence and Natural History of Clinically Silent Episodes of Atrial Fibrillation in Hypertrophic Cardiomyopathy. (2017) (27)
Myths about surgical myectomy: rumors of its death have been greatly exaggerated. (2008) (26)
Progression of Myocardial Fibrosis in Hypertrophic Cardiomyopathy: A Cardiac Magnetic Resonance Study. (2020) (26)
Long-Term Assessment of Electrocardiographic and Echocardiographic Findings in Norwegian Elite Endurance Athletes (2008) (26)
Perspectives on cardiovascular screening. (2015) (26)
Association Between Race and Clinical Profile of Patients Referred for Hypertrophic Cardiomyopathy. (2018) (26)
Athlete’s heart electrocardiogram mimicking hypertrophic cardiomyopathy (2001) (25)
Onset of apical hypertrophic cardiomyopathy in adulthood. (2011) (25)
Commentary and re-appraisal: surgical septal myectomy vs. alcohol ablation: after a decade of controversy and mismatch between clinical practice and guidelines. (2012) (24)
Efficacy of bystander cardiopulmonary resuscitation and out-of-hospital automated external defibrillation as life-saving therapy in commotio cordis. (2005) (24)
Clinical Profile of Nonresponders to Surgical Myectomy with Obstructive Hypertrophic Cardiomyopathy. (2018) (24)
Contemporary surgical management of hypertrophic cardiomyopathy, the need for more myectomy surgeons and disease-specific centers, and the Tufts initiative. (2013) (24)
Sexual Activity and Cardiovascular Disease : A Scientific Statement From the (2012) (24)
Frequency and significance of M-mode echocardiographic evidence of mitral valve prolapse in clinically isolated pure mitral regurgitation: analysis of 65 patients having mitral valve replacement. (1984) (24)
Myofibrillar abnormalities following cardiac muscle cell injury. (1975) (24)
Comparison of circadian rhythm patterns in Tako-tsubo cardiomyopathy versus ST-segment elevation myocardial infarction. (2012) (24)
The dilemma of left ventricular outflow tract obstruction and sudden death in hypertrophic cardiomyopathy: do patients with gradients really deserve prophylactic defibrillators? (2006) (23)
It is not prudent to allow all athletes with implantable-cardioverter defibrillators to participate in all sports. (2008) (23)
Sudden death due to neck blows among amateur hockey players. (2003) (23)
Familial spontaneous complete heart block in hypertrophic cardiomyopathy. (1986) (23)
Canine hypertrophic cardiomyopathy. (1979) (23)
Asymptomatic sinus of Valsalva aneurysm causing right ventricular outflow obstruction before and after rupture. (1984) (23)
Clinical Spectrum and Management Implications of Left Ventricular Outflow Obstruction With Mild Ventricular Septal Thickness in Hypertrophic Cardiomyopathy. (2018) (23)
Perspectives on the Overall Risks of Living With Hypertrophic Cardiomyopathy (2017) (23)
Historical observation on commotio cordis. (2006) (23)
Heart disease and other causes of sudden death in young athletes. (1998) (23)
Nonobstructive Hypertrophic Cardiomyopathy Out of the Shadows: Known from the Beginning but Largely Ignored … Until Now. (2017) (23)
Relation of 12-lead electrocardiogram patterns to implanted defibrillator-terminated ventricular tachyarrhythmias in hypertrophic cardiomyopathy. (2009) (23)
Pilots, hypertrophic cardiomyopathy, and issues of aviation and public safety. (2004) (23)
CLINICAL STUDIES Hypertrophic Cardiomyopathy Development of Left Ventricular Hypertrophy in Adults With Hypertrophic Cardiomyopathy Caused by Cardiac Myosin-Binding Protein C Gene Mutations (2001) (23)
LGE Means Better Selection of HCM Patients for Primary Prevention Implantable Defibrillators. (2016) (23)
Identical twins with hypertrophic cardiomyopathy and apical aneurysm. (2006) (22)
Ethics of preparticipation cardiovascular screening for athletes (2015) (22)
Comparison of amount of myocardial cell disorganization in operatively excised septectomy specimens with amount observed at necropsy in 18 patients with hypertrophic cardiomyopathy. (1980) (22)
Hypertrophic cardiomyopathy characterized by marked hypertrophy of the posterior left ventricular free wall: significance and clinical implications. (1991) (22)
Images in clinical medicine. Commotio cordis. (2002) (22)
Cardiac arrest in a young marathon runner (2002) (22)
EVOLUTION OF RISK STRATIFICATION AND SUDDEN DEATH PREVENTION IN HYPERTROPHIC CARDIOMYOPATHY: 20 YEARS WITH THE IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR. (2021) (22)
Images in cardiovascular medicine. Extreme left ventricular hypertrophy. (1995) (22)
Evidence That High Catecholamine Levels Produced by Pheochromocytoma May be Responsible for Tako-Tsubo Cardiomyopathy. (2015) (22)
Sudden Death in Hypertrophic Cardiomyopathy (2009) (22)
Return to Play for Athletes After COVID-19 Infection: The Fog Begins to Clear. (2021) (21)
Clinical course of middle-aged asymptomatic patients with hypertrophic cardiomyopathy. (1992) (21)
Novel hypertrophic cardiomyopathy phenotype: segmental hypertrophy isolated to the posterobasal left ventricular free wall. (2010) (21)
Arrhythmias and Sudden Death in Athletes (2000) (21)
Risk Stratification and Prevention of Sudden Death in Hypertrophic Cardiomyopathy (2002) (21)
Diversity of views from Europe on national preparticipation screening for competitive athletes. (2010) (21)
Truncus arteriosus malformation in a human embryo. (1972) (21)
Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 13: Commotio Cordis: A Scientific Statement From the American Heart Association and American College of Cardiology. (2015) (21)
Intranuclear glycogen deposits in human cardiac muscle cells: ultrastructure and cytochemistry. (1975) (20)
Shared decision-making in HCM (2017) (20)
Comparison of mitral valve dimensions in adults with valvular aortic stenosis, pure aortic regurgitation and hypertrophic cardiomyopathy. (1993) (20)
Precordial thump for cardiac arrest is effective for asystole but not for ventricular fibrillation. (2009) (20)
Abstract 3872: Profile and Frequency of Sudden Deaths in 1,463 Young Competitive Athletes: From a 25-year U.S. National Registry, 1980 2005 (2006) (20)
Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 15: Legal Aspects of Medical Eligibility and Disqualification Recommendations: A Scientific Statement From the American Heart Association and American College of Cardiology. (2015) (20)
Legal considerations that affect medical eligibility for competitive athletes with cardiovascular abnormalities and acceptance of Bethesda Conference recommendations. (1994) (20)
Hypertrophic cardiomyopathy, myocarditis, and other myopericardial diseases and mitral valve prolapse (1994) (20)
The 20 advances that have defined contemporary hypertrophic cardiomyopathy. (2015) (19)
Perspectives on the failure of pharmaceutical and medical device industries to fully protect public health interests. (2007) (19)
Sudden infant death syndrome (SIDS): cardiac pathologic observations in infants with SIDS. (1977) (19)
Ethical, legal and practical considerations affecting medical decision-making in competitive athletes. (1994) (19)
Q waves in hypertrophic cardiomyopathy: a reassessment. (1990) (19)
Pitfalls in clinical recognition and a novel operative approach for hypertrophic cardiomyopathy with severe outflow obstruction due to anomalous papillary muscle. (1999) (19)
Risk profiles and cardiovascular preparticipation screening of competitive athletes. (1997) (19)
Sudden Unexpected Death Due to Myocarditis in Young People, Including Athletes. (2020) (18)
Morphologic evidence for "small vessel disease" in patients with hypertrophic cardiomyopathy. (1987) (18)
In defense of antimicrobial prophylaxis for prevention of infective endocarditis in patients with hypertrophic cardiomyopathy. (2009) (18)
Safety, Side Effects and Relative Efficacy of Medications for Rhythm Control of Atrial Fibrillation in Hypertrophic Cardiomyopathy. (2019) (18)
Fabry Disease in Families With Hypertrophic Cardiomyopathy: Clinical Manifestations in the Classic and Later-Onset Phenotypes (2017) (18)
Perianesthetic Management of Hypertrophic Cardiomyopathy (2006) (18)
Legal considerations that affect medical eligibility for competitive athletes with cardiovascular abnormalities and acceptance of Bethesda Conference recommendations. (1994) (18)
Cardiac symptoms before sudden cardiac death caused by hypertrophic cardiomyopathy: a nationwide study among the young in Denmark. (2016) (18)
Structurally Normal Hearts Are Uncommonly Associated With Sudden Deaths in Athletes and Young People. (2019) (18)
Left ventricular apical aneurysm in hypertrophic cardiomyopathy as a risk factor for sudden death at any age (2018) (17)
Management of Hypertrophic Cardiomyopathy: JACC State-of-the-Art Review. (2022) (17)
Prevalence and characteristics of disporportionate ventricular septal thickening in infants with congenital heart disease. (1979) (17)
The spectrum of degenerative changes in hypertrophied human cardiac muscle cells: an ultrastructural study. (1975) (17)
Diagnostic Utility of Cardiac Magnetic Resonance Imaging in Monozygotic Twins With Hypertrophic Cardiomyopathy and Identical Pattern of Left Ventricular Hypertrophy (2007) (17)
Apical hypertrophic cardiomyopathy developing at a relatively advanced age. (2001) (17)
The 2009 international hypertrophic cardiomyopathy summit. (2010) (17)
Efficacy of Combined Cox-Maze IV and Ventricular Septal Myectomy for Treatment of Atrial Fibrillation in Patients With Obstructive Hypertrophic Cardiomyopathy. (2019) (17)
Alcohol septal ablation: in which patients and why? (2017) (17)
Survival Following Alcohol Septal Ablation or Septal Myectomy for Patients With Obstructive Hypertrophic Cardiomyopathy. (2022) (16)
Obstructive hypertrophic cardiomyopathy associated with minimal left ventricular hypertrophy. (1984) (16)
A Guide to Hypertrophic Cardiomyopathy: For Patients, Their Families, and Interested Physicians (2013) (16)
Is It Fair to Screen Only Competitive Athletes for Sudden Death Risk, or Is It Time to Level the Playing Field? (2018) (16)
Operative treatment of pediatric obstructive hypertrophic cardiomyopathy: a 26-year experience. (1993) (16)
Cardiac evaluation of collegiate student athletes: a medical and legal perspective. (2012) (16)
Counterpoint: Mandatory ECG screening of young competitive athletes. (2012) (16)
Obstructive vs nonobstructive asymmetric septal hypertrophy: Differences in left ventricular function with exercise (1978) (16)
Intramitochondrial gylcogen deposits in hypertrophied human myocardium. (1975) (15)
Ventricular septal crypt in hypertrophic cardiomyopathy. (2010) (15)
Acquired left ventricular endocardial constriction from massive mural calcific deposits: a newly recognized cause of impairment to left ventricular filling. (1984) (15)
Echocardiographic assessment of left ventricular hypertrophy in patients with obstructive or nonobstructive hypertrophic cardiomyopathy. (1983) (15)
Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 14: Sickle Cell Trait: A Scientific Statement From the American Heart Association and American College of Cardiology. (2015) (15)
Strychnine poisoning successfully treated with diazepam. (1971) (15)
Racial variations in the childhood electrocardiogram: preliminary observations. (1972) (15)
Unusual distribution of left ventricular hypertrophy in obstructive hypertrophic cardiomyopathy: localized posterobasal free wall thickening in two patients. (1985) (15)
Eugene Braunwald, MD and the early years of hypertrophic cardiomyopathy: a conversation with Dr. Barry J. Maron. (2012) (15)
Myocardial disorganisation in hypertrophic cardiomyopathy. Another point of view. (1983) (15)
Ventricular arrhythmias, sudden death, and prevention in patients with hypertrophic cardiomyopathy (2000) (14)
There is No Reason to Adopt ECGs and Abandon American Heart Association/American College of Cardiology History and Physical Screening for Detection of Cardiovascular Disease in the Young (2019) (14)
The 25-Year Genetic Era in Hypertrophic Cardiomyopathy: Revisited (2014) (14)
merican Heart Association/American College of Cardiology oundation/Heart Rhythm Society Scientific Statement on oninvasive Risk Stratification Techniques for Identifying atients at Risk for Sudden Cardiac Death (2008) (14)
Racial Frequencies in Congenital Heart Disease (1973) (14)
American Heart Association/American College of Cardiology Foundation/Heart Rhythm Society Scientific Statement on Noninvasive Risk Stratification Techniques for Identifying Patients at Risk for Sudden Cardiac Death (2008) (14)
Echocardiographic analysis of ventricular septal dynamics in hypertrophic cardiomyopathy and other diseases. (1984) (14)
Importance and feasibility of creating hypertrophic cardiomyopathy centers in developing countries: the experience in India. (2015) (14)
Foundation/American Heart Association Task Force on Practice Guidelines Cardiomyopathy : A Report of the American College of Cardiology 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic (2011) (14)
Hypertrophic Cardiomyopathy in Athletes. (1993) (14)
Genetics of Hypertrophic Cardiomyopathy After 20 Years (2012) (14)
Sudden death while playing professional football. (1981) (13)
Experimental production of aortic valvular stenosis. Short-term and long-term studies in dogs. (1974) (13)
Cardiology patient pages. Hypertrophic cardiomyopathy. (2002) (13)
Relation of Doppler Tissue Imaging Parameters With Heart Failure Progression in Hypertrophic Cardiomyopathy. (2016) (13)
The differential diagnosis of anomalies of the great vessels by real-time, two-dimensional echocardiography (1974) (13)
Revisiting Athlete's Heart Versus Pathologic Hypertrophy: ARVC and the Right Ventricle. (2017) (13)
Sarcolemmal alterations in cardiac hypertrophy and degeneration. (1976) (13)
Marginal overlap between electrocardiographic abnormalities in patients with hypertrophic cardiomyopathy and trained athletes: Implications for preparticipation screening (2007) (13)
Hypertrophic cardiomyopathy: one gene … but many phenotypes. (2014) (13)
Molecular epidemiology of hypertrophic cardiomyopathy. (2002) (13)
Revisiting arrhythmic risk after alcohol septal ablation: is the pendulum finally swinging…back to myectomy? (2014) (13)
Hypertrophic Cardiomyopathy and Sudden Death Initially Identified at Autopsy. (2020) (13)
Prediction and Prevention of Sudden Death in Young Patients (<20 years) With Hypertrophic Cardiomyopathy. (2020) (13)
Sudden unexpected death 12 years after "near-miss" sudden infant death syndrome in infancy. (1986) (13)
Sudden Death in Patients with Hypertrophic Cardiomyopathy (1980) (13)
Erratum: Task force on sudden cardiac death of the European society of cardiology (European Heart Journal (2001) 22 (1374-1450)) (2002) (12)
Inter Association Task Force Recommendations on Emergency Preparedness andManagement of Sudden Cardiac Arrest in High School andCollege Athletic Programs: A Consensus Statement (2007) (12)
Septicemia following traumatic or incidental splenectomy. (1972) (12)
Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 13 Commotio Cordis A Scientific Statement From the American Heart Association and American College of Cardiology (2015) (12)
Variations in flow-velocity waveforms obtained by pulsed Doppler echocardiography in the normal human aorta. (1986) (12)
Massive cardiac ventricular scarring in first-degree relatives with hypertrophic cardiomyopathy. (1984) (12)
Spontaneous Animal Models (2007) (12)
A Discussion of Contemporary Nomenclature, Diagnosis, Imaging, and Management of Patients With Hypertrophic Cardiomyopathy. (2016) (12)
The occurrence of α-glycogen in human cardiac muscle cells (1974) (12)
Hypertrophic cardiomyopathy: the great masquerader. Clinical conference from the Cardiology Branch of the National Heart, Lung, and Blood Institute, Bethesda, Md. (1978) (12)
Medical and surgical therapy of hypertrophic cardiomyopathy. (1988) (12)
Importance of the autonomic nervous system in an experimental model of commotio cordis. (2006) (12)
Under-recognition of aortic and aortic valve disease and the risk for sudden death in competitive athletes. (2015) (12)
Hypertrophic cardiomyopathy: an overview. (1980) (12)
Ventricular tachycardia/fibrillation early after defibrillator implantation in patients with hypertrophic cardiomyopathy is explained by a high-risk subgroup of patients. (2013) (12)
Nongenetically transmitted disproportionate ventricular septal thickening associated with left ventricular outflow obstruction. (1979) (12)
Impact of Effective Management Strategies on Patients With the Most Extreme Phenotypic Expression of Hypertrophic Cardiomyopathy. (2019) (12)
Sudden death from collapsing sand holes. (2007) (12)
Detection of intralesional calcium in coronary arteries. (1996) (12)
Hypertrophic cardiomyopathy compatible with successful completion of the marathon. (1984) (12)
Coexistence of asymmetric and symmetric left ventricular hypertrophy in a family with hypertrophic cardiomyopathy. (1982) (11)
Usefulness of Global Longitudinal Strain to Predict Heart Failure Progression in Patients With Nonobstructive Hypertrophic Cardiomyopathy. (2021) (11)
Electrocardiographic evidence of left ventricular hypertrophy in otherwise normal children. Clarification by echocardiography. (1975) (11)
Early descriptions of sudden cardiac death due to commotio cordis occurring in baseball. (2010) (11)
Electrocardiographic changes associated with training and discontinuation of training in an athlete with hypertrophic cardiomyopathy. (2004) (11)
Spontaneous echo contrast and thromboembolism. (1997) (11)
Cardiomyopathies in the first two decades of life. (1981) (10)
New interventions for obstructive hypertrophic cardiomyopathy: promise and prudence. (1999) (10)
Causes of sudden death in competitive athletes: Correction (1986) (10)
Selective cine coronary arteriography and vectorcardiographic diagnose: correlative study of one hundred patients. (1971) (10)
Catastrophic Injuries in High School and College Sports (1996) (10)
Corrigendum to: ‘Recommendations for interpretation of 12-lead electrocardiogram in the athlete’ [Eur Heart J 2010;31:243–259] (2010) (10)
HCM in the general population. (1996) (10)
A phenocopy of sarcomeric hypertrophic cardiomyopathy: LAMP2 cardiomyopathy (Danon disease) from China. (2012) (10)
Sudden death and hypertrophic cardiomyopathy (2001) (10)
Hypertrophic cardiomyopathy in the developing world: focus on India. (2014) (10)
Isolation and Characterization of Myosin from Subjects with Asymmetric Sepatal Hypertrophy (1977) (10)
Extreme hypertrophic cardiomyopathy (2003) (10)
Comparison of phenotypic expression of hypertrophic cardiomyopathy in patients from the United States and Germany. (1999) (10)
Simultaneous occurrence of mitral valve prolapse and systolic anterior motion in hypertrophic cardiomyopathy. (1991) (10)
Impact of Postgraduate Medical Education on Recognition of Stroke (2005) (10)
839-1 The long-term effect of surgical myectomy on survival in patients with obstructive hypertrophic cardiomyopathy (2004) (10)
Prognostic role of left ventricular apical aneurysm in hypertrophic cardiomyopathy: A systematic review and meta-analysis. (2021) (9)
Hypertrophic cardiomyopathy and complete heart block in infancy. (1981) (9)
Hypertrophic Cardiomyopathy (2002) (9)
Coexistence of acute takotsubo syndrome and acute coronary syndrome (2019) (9)
Disproportionate ventricular thickening in patients with systemic hypertension. (1978) (9)
Cardiac muscle cell disorganization in the ventricular septum: Evidence from quantitative histology that it is a highly sensitive marker of hypertrophic cardiomyopathy (1978) (9)
Posterior cardiac displacement by anterior mediastinal tumor. (1980) (9)
Hypertrophic Cardiomyopathy With Apical Aneurysm (2004) (9)
Abstract 13294: Evidence for Reduced Mortality in an Adult Cohort With Hypertrophic Cardiomyopathy (2013) (9)
Recognition of hypertrophic cardiomyopathy as a contemporary, relatively common, and treatable disease (from the International Summit V). (2014) (9)
Ethical, legal, and practical considerations impacting medical decision-making in competitive athletes. (1994) (9)
Clinical profile and spectrum of commotio cordis (2002) (9)
Erratum: 26th Bethesda conference: Recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities (Medicine and Science in Sports and Exercise (26:10) (S223-S283)) (1994) (9)
Profound left ventricular remodeling associated with LAMP2 cardiomyopathy. (2010) (9)
Case for Earlier Surgical Myectomy in Patients With Obstructive Hypertrophic Cardiomyopathy. (2018) (9)
Ultrastructural aspects of contractile proteins in cardiac hypertrophy and failure. (1976) (8)
Eligibility and Disquali fi cation Recommendations for Competitive Athletes With Cardiovascular Abnormalities : Preamble , Principles , and General Considerations (2015) (8)
A Lethal Blow to the Chest as an Underdiagnosed Cause of Sudden Death in United Kingdom Sports (Football, Cricket, Rugby). (2019) (8)
Patterns of pulmonary venous and transmitral flow velocity in patients with hypertrophic cardiomyopathy. (1995) (8)
The first patient clinically diagnosed with hypertrophic cardiomyopathy. (2008) (8)
Long-Term Outcome in High-Risk Patients With Hypertrophic Cardiomyopathy After Primary Prevention Defibrillator Implants (2020) (8)
Stress cardiomyopathy. Authors' reply (2007) (8)
The Father of Septal Myectomy for Obstructive HCM, Who Also Had HCM: The Unbelievable Story. (2016) (8)
Implantable cardioverter defibrillators for primary prevention of sudden death in hypertrophic cardiomyopathy (2016) (8)
Sports and arrhythmias: a report of the International Workshop Venice Arrhythmias 2009 (2010) (8)
The editor's roundtable: sudden cardiac death in athletes. (2007) (8)
Underappreciated occurrence of discrete subaortic membranes producing left ventricular outflow obstruction in hypertrophic cardiomyopathy (2017) (8)
Development of endocardial valvuloids with valvular insufficiency. (1972) (8)
Benefit of Cardiac Resynchronization Therapy in End-Stage Nonobstructive Hypertrophic Cardiomyopathy. (2019) (8)
Images in cardiovascular medicine. Diagnostic utility of cardiac magnetic resonance imaging in monozygotic twins with hypertrophic cardiomyopathy and identical pattern of left ventricular hypertrophy. (2007) (7)
Prevalence and Characteristics of Disproportionate Ventricular Septal Thickening in Infants with Congenital Heart Disease (1979) (7)
Hypertrophic cardiomyopathy mimicking pericardial constriction or myocardial restriction. (1981) (7)
Genetic Screening of Sperm and Oocyte Donors : Ethical and Policy Implications (2011) (7)
Sudden death and other risks associated with dry-sand beach holes. (2001) (7)
Coronary embolization in hypertrophic cardiomyopathy with left ventricular apical aneurysm. (2015) (7)
Hypertrophic cardiomyopathy in myosin-binding protein C (MYBPC3) Icelandic founder mutation carriers (2020) (7)
HLA linkage vs association in hypertrophic cardiomyopathy. Evidence for the absence of an association in a heterogeneous Caucasian population. (1982) (7)
Clinical Course and Management of Hypertrophic Cardiomyopathy. (2018) (7)
Abstract 14156: Risk Stratification and Outcome of Patients with Hypertrophic Cardiomyopathy Over 60 Years of Age: Does Age Count? (2011) (7)
Hypertrophic Cardiomyopathy in Monozygotic Twins (2002) (7)
The electrocardiogram in supravalvular aortic stenosis. (1971) (7)
Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 15: Legal Aspects of Medical Eligibility and Disqualification Recommendations: A Scientific Statement From the American Heart Association and American College of Cardiology. (2015) (7)
Appearance of or persistence of severe mitral regurgitation without left ventricular outflow obstruction after partial ventricular septal myotomy-myectomy in hypertrophic cardiomyopathy. (1991) (7)
Constitutively active AMP kinase mutations cause WPW and glycogen storage disease mimicking hypertrophic cardiomyopathy (2002) (7)
Association of secundum atrial septal defect and atrioventricular nodal dysfunction. A genetically transmitted syndrome. (1978) (6)
Sudden Cardiac Death in Competitive Athletes (1997) (6)
Daughter-mother tako-tsubo cardiomyopathy. (2013) (6)
Successful therapeutic hypothermia in patients with hypertrophic cardiomyopathy. (2011) (6)
The giant negative T wave revisited ... in hypertrophic cardiomyopathy. (1990) (6)
Hypertrophic Cardiomyopathy: New Concepts and Therapies. (2022) (6)
Outcomes Over Follow-up ≥10 Years After Surgical Myectomy for Symptomatic Obstructive Hypertrophic Cardiomyopathy (2021) (6)
Chapter 9. ST Segment Elevation and Sudden Death in the Athlete (2007) (6)
Two-dimensional Echocardiographic Assessment of the Idiopathic Hypereosinophilic Syndrome (2005) (6)
Diagnosis and management of hypertrophic cardiomyopathy (2004) (6)
Cardiomyopathies characterized by evidence of resistance to left ventricular inflow. (1980) (6)
Electrocardiogram in hypertrophic cardiomyopathy revisited: does ECG pattern predict phenotypic expression and left ventricular hypertrophy or sudden death? (2002) (6)
Pathophysiology and Clinical Consequences of Atrial Fibrillation in Hypertrophic Cardiomyopathy (2007) (6)
Lutembacher's syndrome. (1997) (6)
Reply: Hypertrophic Cardiomyopathy With Left Ventricular Apical Aneurysm. (2017) (6)
Longevity in elite athletes: the first 4-min milers (2018) (6)
Unusual long-term survival following cardiac arrest in hypertrophic cardiomyopathy. (1983) (6)
The electrocardiographic diagnosis of left ventricular hypertrophy in apparently normal children. (1973) (6)
Significance of Appropriate Defibrillator Shock 3 Hours and 20 Minutes Following Implantation in a Patient with Hypertrophic Cardiomyopathy (2008) (6)
A Scientific Statement From the American Heart Association Council on Clinical Cardiology Committee on Electrocardiography and Arrhythmias and Council on Epidemiology and Prevention (2008) (6)
Upper limits of physiologically induced left ventricular cavity enlargement due to athletic training.: 1078 (1995) (6)
Distinctive Hypertrophic Cardiomyopathy Anatomy and Obstructive Physiology in Patients Admitted With Takotsubo Syndrome. (2020) (6)
Cardiovascular screening for young athletes--reply. (2015) (6)
Importance of Newer Cardiac Magnetic Resonance-Based Risk Markers for Sudden Death Prevention in Hypertrophic Cardiomyopathy:An International Multicenter Study (2021) (5)
Long-term postoperative prognosis of patients with congenital heart disease. Clinical conference from the Cardiology Branch of the National Heart, Lung, and Blood Institute. (1977) (5)
Surgical septal myectomy for hypertrophic cardiomyopathy in Greece: a single-center initial experience. (2014) (5)
Hypertrophic Cardiomyopathy: Is a 'Cure' Coming . . . Or Is It Already Here? (2020) (5)
Abstract 2441: Evolution Over 8 Years of the US Preparticipation Screening Process for Unsuspected Cardiovascular Disease in US High School Athletes (2006) (5)
Distribution and Significance of Cardiac Muscle Cell Disorganization in the Left Ventricle of Patients with Hypertrophic Cardiomyopathy: Evidence of a Diffuse Cardiomyopathic Process (1982) (5)
Hypertrophic cardiomyopathy in China. (2007) (5)
Sexual Activity and Cardiovascular Disease : A Scientific Statement From the American (2012) (5)
Altered intercellular communication and extracellular matrix signaling as a potential disease mechanism in human hypertrophic cardiomyopathy (2021) (5)
Cardiovascular Causes and Pathology of Sudden Death in Athletes: The American Experience (2000) (5)
Crisscrossed atrioventricular valves and prolonged survival. (1982) (5)
The ESC Risk Score is Less Reliable than ACC/AHA Risk Factors in Hypertrophic Cardiomyopathy: When Sensitivity Trumps Specificity. (2019) (5)
Abstract 15915: Gender Matters in the Risk for Sudden Death in Young Competitive Athletes (2014) (5)
Saving Lives One at a Time. (2016) (5)
Infective endocarditis in hypertrophic cardiomyopathy: Analysis of 5 patients requiring mitral valve replacement (1982) (5)
CARDIAC HYPERTROPHY IN ATHLETES (1991) (5)
Refractory hypochromic anemia in malignant lymphoma. (1970) (5)
Long-term consequences of the right ventricular pacing mania of the 1990s for obstructive hypertrophic cardiomyopathy. (2014) (5)
LAMP2 Cardiomyopathy: Consequences of Impaired Autophagy in the Heart (2021) (5)
Adult Monozygotic Twins With Hypertrophic Cardiomyopathy and Identical Disease Expression and Clinical Course. (2020) (5)
Surgical Approaches to Hypertrophic Obstructive Cardiomyopathy. (2018) (5)
Cardiovascular Disease in Ankylosing (Marie-Strümpell) Spondylitis (1997) (5)
Echocardiographic Identification of Patterns of Left Ventricular Hypertrophy in Hypertrophic Cardiomyopathy (1982) (5)
Hypertrophic Cardiomyopathy in "Real-World" Community Cardiology Practice. (2020) (5)
Editorial : Myocardial Fiber Disarray and Ventricular Septal Hypertrophy In Asymmetrical Hypertrophy of the Heart (5)
[Prevention of sudden death with the implantable defibrillator in hypertrophic cardiomyopathy]. (2006) (5)
Historical perspectives on the implantable cardioverter-defibrillator and prevention of sudden death in hypertrophic cardiomyopathy. (2015) (5)
Safety of Sports for Patients With ICDs: Results of a Prospective Multinational Registry (2012) (4)
Spontaneously Occurring Hypertrophic Cardiomyopathy in Dogs and Cats: A Potential Animal Model of a Human Disease (1982) (4)
Resuscitation in a biological model of commotio cordis, sudden death from low energy chest wall impact (1998) (4)
Both aborted sudden cardiac death and end-stage phase in hypertrophic cardiomyopathy. (1993) (4)
Reply: What Is the True Prevalence of Hypertrophic Cardiomyopathy? (2015) (4)
Death and Cardiac Arrest in U.S. Triathlon Participants (2018) (4)
Scope of the Problem of Sudden Death in Athletes: Definitions, Epidemiology and Socioeconomic Implications (2000) (4)
Prevention of sudden death for patients with cardiomyopathies another step forward. (2012) (4)
END-STAGE HYPERTROPHIC CARDIOMYOPATHY REVISITED: IMPACT OF CONTEMPORARY THERAPIES (2019) (4)
Coarctation of the aorta in the adult. (1979) (4)
Evolution of Left Ventricular Hypertrophy in Patients with Hypertrophic Cardiomyopathy (1990) (4)
Surgical Ventricular Septal Myectomy in the Developing World. (2016) (4)
Sarcomere protein gene mutations: A frequent cause of elderly-onset hypertrophic cardiomyopathy. (2000) (4)
What is commotio cordis? (1999) (4)
Evidence That Subcutaneous Implantable Cardioverter-Defibrillators Are Effective and Reliable in Hypertrophic Cardiomyopathy. (2020) (4)
Preparticipation Cardiovascular Screening for Young Athletes—Reply (2000) (4)
A discussion on hypertrophic cardiomyopathy. (1978) (4)
Anatomic validation of late gadolinium enhancement as evidence of myocardial scarring in LAMP2 cardiomyopathy. (2017) (4)
Coexistence of passive and active junctional rhythms with rates up to 300 per minute in a child with atrial parasystole. (1973) (4)
Clinical course of patients with hypertrophic cardiomyopathy. (1979) (4)
Left Ventricular Hypertrophy in Athletes Physiologic Limits of Left Ventricular Hypertrophy in Elite Junior Athletes: Relevance to Differential Diagnosis of Athlete's Heart and Hypertrophic Cardiomyopathy (2002) (4)
Efficacy of 24 hour ambulatory ecg monitoring as a predictor of sudden death in hypertrophic cardiomyopathy (1981) (4)
Does preparticipation cardiovascular screening of athletes save lives? (2007) (4)
Survival After Takotsubo, Revisited. (2018) (4)
Future Role of New Negative Inotropic Agents in the Era of Established Surgical Myectomy for Symptomatic Obstructive Hypertrophic Cardiomyopathy (2022) (3)
Impact of comorbidities on atrial fibrillation and sudden cardiac death in hypertrophic cardiomyopathy (2021) (3)
Recurrence of a discrete subaortic membrane 27 years after operative resection. (1995) (3)
Hypertrophic Cardiomyopathy in Japan: Clinical, Morphologic and Genetic Expression (2007) (3)
Coexistence of late gadolinium enhancement due to myocardial infarction and hypertrophic cardiomyopathy (2011) (3)
Ventricular Septal Myectomy for Obstructive Hypertrophic Cardiomyopathy (Analysis Spanning 60 Years Of Practice): AJC Expert Panel. (2022) (3)
Changing Demographics in Hypertrophic Cardiomyopathy and Implications for Management: Clinical Research. (2022) (3)
Other Modes of Disability or Death Including Stroke, and Treatment Strategies, in Hypertrophic Cardiomyopathy (2007) (3)
Back to the Future: Predicting Sudden Death in Hypertrophic Cardiomyopathy Relyingon Individual Risk Markers and Physician Judgment Without Mathematical Scoring. (2020) (3)
Significance and relationship between magnitude of left ventricular hypertrophy and congestive heart failure symptoms in hypertrophic cardiomyopathy (2002) (3)
26th Bethesda conference: recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities. Task Force 3: hypertrophic cardiomyopathy, myocarditis and other myopericardial diseases and mitral valve prolapse. (1994) (3)
Disparity between unusual left ventricular morphology and clinical presentation and course in hypertrophic cardiomyopathy. (2010) (3)
Single Coil Implantable Cardioverter Defibrillator Leads in Patients With Hypertrophic Cardiomyopathy. (2020) (3)
The "Guidant Affair": 15 years later. (2020) (3)
THE GUIDANT AFFAIR REVISITED…BUT THIS TIME WITH GOOD NEWS. (2020) (3)
Aborted Sudden Cardiac Death in Hypertrophic Cardiomyopathy (1999) (3)
Is Regression of Left Ventricular Hypertrophy Really a Good Thing for Patients with Hypertrophic Cardiomyopathy?: The Emerging Mavacamten Story. (2021) (3)
Prolapse of the mitral valve is described in two patients with the Ebstein's anomaly of the tricuspid. (1976) (3)
[Risk stratification for sudden death in hypertrophic cardiomyopathy]. (2007) (3)
Reply: Obstructive sleep apnea and hypertrophic cardiomyopathy: obiter dictum or more? (2014) (3)
Cardiovascular Causes of Sudden Death, Preparticipation Screening, and Criteria for Disqualification in Young Athletes (2007) (3)
Response: How common is comorbid takotsubo syndrome in patients with acute coronary syndromes? (2019) (3)
Unusual complications of meningococcal meningitis. (1972) (3)
Symposium on the athlete heart (1986) (3)
Development and Validation of a Clinical Predictive Model for Identifying Hypertrophic Cardiomyopathy Patients at Risk for Atrial Fibrillation (2021) (2)
Temporal and Global Trends of the Incidence of Sudden Cardiac Death in Hypertrophic Cardiomyopathy. (2022) (2)
Syndrome of Reversible Cardiogenic Shock and Left Ventricular Ballooning in Obstructive Hypertrophic Cardiomyopathy (2021) (2)
The Young Competitive Athlete: Causes of Sudden Death, Detection, Preparticipation Screening, and Standards for Disqualification with Cardiovascular Abnormalities (1997) (2)
Can sudden cardiac death be prevented? (2010) (2)
Images in cardiovascular medicine. Hypertrophic cardiomyopathy in monozygotic twins. (2002) (2)
Harvey Feigenbaum, MD, and the Creation of Clinical Echocardiography: A Conversation With Barry J. Maron, MD. (2017) (2)
Prevention of Sudden Death in Hypertrophic Cardiomyopathy (2004) (2)
What Causes Hypertrophic Cardiomyopathy? (2022) (2)
Size as an Important Determinant of Chest Blow–induced Commotio Cordis (2018) (2)
Recurrent commotio cordis: Déjà vu (2015) (2)
THE MYOCARDIAL CONTRACTION FRACTION (MCF) IS ASSOCIATED WITH NYHA CLASS AS WELL AS DELAYED ENHANCEMENT BY CARDIAC MRI IN HYPERTROPHIC CARDIOMYOPATHY AND PREDICTS SUDDEN CARDIAC DEATH (2016) (2)
Diagnosis and Evaluation of Hypertrophic Cardiomyopathy (2022) (2)
Nonobstructive Hypertrophic Cardiomyopathy: Overlooked But Not Forgotten. (2016) (2)
Intraventricular muscle band mimicking asymmetric ventricular septal hypertrophy and hypertrophic cardiomyopathy. (1992) (2)
Electrocardiography and Preparticipation Screening of Competitive High School Athletes (2010) (2)
Dyslipoproteinemia in North America: The Lipid Research Clinics Program Prevalence Study. (1986) (2)
The Case for Takotsubo Cardiomyopathy (Syndrome) as a Variant of Acute Myocardial Infarction. (2018) (2)
Response by Rowin et al to Letter Regarding Article, "Clinical Profile and Consequences of Atrial Fibrillation in Hypertrophic Cardiomyopathy". (2018) (2)
After 60 Years Hypertrophic Cardiomyopathy is Finally Recognized as a Contemporary Treatable Disease with Low Mortality and Morbidity. (2020) (2)
DOES FOCAL LATE GADOLINIUM ENHANCEMENT AT THE RIGHT VENTRICULAR INSERTION POINTS MATTER IN RISK STRATIFICATION FOR SUDDEN DEATH IN HYPERTROPHIC CARDIOMYOPATHY (2013) (2)
To the editor--Participation screening for athletes. (2014) (2)
Ventricular Septal Myectomy Decreases Long-Term Risk for Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy. (2022) (2)
Abstract 13139: Prognostic Utility of Contrast-Enhanced Cardiovascular Magnetic Resonance Imaging in Hypertrophic Cardiomyopathy: An International Multicenter Study (2012) (2)
Hypertrophic cardiomyopathy in childhood: the gradient is not the disease. Excessive use of experimental invasive interventions. (2013) (2)
Apical hypertrophic cardiomyopathy. (1997) (2)
Cardiovascular Disease, Sudden Cardiac Death, and Preparticipation Screening in Young Competitive Athletes (2012) (2)
Surviving malignant hypertrophic cardiomyopathy with all major complications in a single patient. (2015) (2)
[Myocardial hypoperfusion due to microvascular dysfunction in hypertrophic cardiomyopathy: role of positron emission tomography]. (2009) (2)
Evidence of Advanced Pulmonary Vascular Remodeling in Obstructive Hypertrophic Cardiomyopathy with Pulmonary Hypertension. (2022) (2)
Sickle Cell Trait and Sudden Death in Athletes-Reply (1996) (2)
Prognostic implications of left ventricular function in endomyocardial disease in infants and children. (1975) (2)
Medical data, the media, and distortion of the facts in the internet era. (2008) (2)
Chronic Heart Failure Is Infrequently Associated With Renal Dysfunction in Hypertrophic Cardiomyopathy. (2019) (2)
LACK OF PHENOTYPIC DIFFERENCES BY CMRI IN THE TWO MOST COMMON SARCOMERE PROTEIN GENE MUTATIONS IN HYPERTROPHIC CARDIOMYOPATHY (2013) (2)
TAKOTSUBO CARDIOMYOPATHY: RISKS ASSOCIATED WITH SEVERE HEART FAILURE AND SYSTEMIC HYPOTENSION (2013) (2)
925-43 Hypertrophic Cardiomyopathy in Tuscany: More Benign Clinical Course and Outcome in an Unselected Regional Population (1995) (2)
Achieving Extended Longevity and Quality of Life for Senior Patients With Hypertrophic Cardiomyopathy: What Is Possible. (2017) (2)
Occurrence of asymmetric septal hypertrophy (ASH) in infancy (1974) (2)
Increasing evidence that risk scores underperform in predicting sudden death in hypertrophic cardiomyopathy (2019) (2)
Functional assessment of left ventricular ejection dynamics by cine-magnetic resonance imaging in hypertrophic cardiomyopathy. (1994) (2)
Dynamic obstruction to left ventricular outflow: the case for its existence in hypertrophic cardiomyopathy. (1987) (2)
Abstract 14017: Contemporary Management Strategies Provide Low Mortality Rates for Young Patients with Hypertrophic Cardiomyopathy (2014) (1)
Does idiopathic left ventricular typertrophy exist (1974) (1)
Implantable Defibrillator for Prevention of Sudden Death in Hypertrophic Cardiomyopathy (2007) (1)
Heritable Disease and Sperm Donation—Reply (2010) (1)
Abstract 2970: Mechanism of Increased Susceptibility of Youth to Sudden Death with Chest Wall Impact (Commotio Cordis) (2007) (1)
PARADIGM CHANGE IN THE DEMOGRAPHICS OF MORTALITY IN HYPERTROPHIC CARDIOMYOPATHY (2015) (1)
Differing strategies for sudden death prevention in hypertrophic cardiomyopathy (2022) (1)
86 – Ventricular Arrhythmias in Hypertrophic Cardiomyopathy (2014) (1)
Contemporary Reviews in Cardiovascular Medicine Contemporary Insights and Strategies for Risk Stratification and Prevention of Sudden Death in Hypertrophic Cardiomyopathy (2010) (1)
Prevalence of Arrhythmias During 24‐Hour Electrocardiographic Monitoring Exercise Testing in Patients with Obstructive Nonobstructive Hypertrophic Cardiomyopathy (1979) (1)
Tuesday, 28 August 2012 (2012) (1)
Hypertrophic cardiomyopathy with left ventricular apical aneurysm: the newest high-risk phenotype. (2020) (1)
Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 14: Sickle Cell Trait: A Scientific Statement From the American Heart Association and American College of Cardiology. (2015) (1)
The LVAD in the Management of Advanced Heart Failure Due to Hypertrophic Cardiomyopathy. (2020) (1)
UNEXPECTED IDENTIFICATION OF FABRY DISEASE AMONG PATIENTS WITH THE CLINICAL DIAGNOSIS OF HYPERTROPHIC CARDIOMYOPATHY IN ICELAND (2014) (1)
Abstract 14979: Progressive Heart Failure is Uncommon in Patients With Nonobstructive Hypertrophic Cardiomyopathy (2013) (1)
LEAFLET-DEPENDENT SPECTRUM OF REGURGITANT JET IN MITRAL VALVE PROLAPSE (1998) (1)
Is septal ablation preferable to surgical myomectomy for obstructive hypertrophic cardiomyopathy? Surgical Myectomy Remains the Primary Treatment Option for Severely Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy C ONTROVERSIES IN C ARDIOVASCULAR M EDICINE (2007) (1)
Abstract 3600: Identification of Hypertrophic Cardiomyopathy in the Community and the Value of Preparticipation Sports Examinations (2006) (1)
Risk of Hypertrophic Cardiomyopathy with Contemporary Management Strategies Implemented In Non-Referral Regional Community-Based Practices. (2020) (1)
Preparticipation screening strategies for prevention of sudden death in young competitive athletes: 12-lead ECG makes the difference (2005) (1)
Abstract 1194: Comparison of Cardiovascular Disease Mortality in Young U.S. and Italian Competitive Athletes: Which Preparticipation Screening Strategy is Really More Effective? (2008) (1)
RACIAL DIFFERENCES IN CLINICAL COURSE AND OUTCOME OF PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY (2018) (1)
The Athlete's Heart, ECG, and Differential Diagnosis with Hypertrophic Cardiomyopathy and Other Cardiomyopathies (2007) (1)
Historical Perspective and Names (2006) (1)
ASSESSMENT OF EUROPEAN SOCIETY OF CARDIOLOGY SUDDEN CARDIAC DEATH RISK MODEL FOR HYPERTROPHIC CARDIOMYOPATHY (2015) (1)
Ten common questions about hypertrophic cardiomyopathy...and misconceptions. (2005) (1)
The Young Competitive Athlete with Heart Disease (1997) (1)
Sixty-Year Evolution of Surgical Myectomy for Symptomatic Obstructive Hypertrophic Cardiomyopathy with Insights From the Historic NIH Surgical Experience to Present. (2022) (1)
Late gadolinium enhancement score (LGE-Score) for prediction of extensive late gadolinium enhancement in hypertrophic cardiomyopathy (2015) (1)
Common Variant on Chromosome 9p21 Predicts Severity of Coronary Artery Disease (2011) (1)
PRKAG2 Glycogen Storage Disease Cardiomyopathy: Out of the Darkness and Into the Light. (2020) (1)
Arrhythmias and Clinical EPATRIAL FIBRILLATION IS ASSOCIATED WITH LOW CARDIOVASCULAR MORTALITY IN HYPERTROPHIC CARDIOMYOPATHY (2017) (1)
Patterns and significance of the distribution of left ventricular hypertrophy in a large population of patients with hypertrophic cardiomyopathy: A wide-angle two-dimensional echocardiographic study (1980) (1)
Apical hypertrophic cardiomyopathy: a view from the U. S. A. (1986) (1)
What Constitutes an "Academic" Cardiology Practice? There Are New Models to Consider. (2015) (1)
Multicenter Study of the Efﬁcacy and Safety of Disopyramide in Obstructive Hypertrophic Cardiomyopathy (2005) (1)
New observations on the interrelation of dynamic subaortic obstruction and exercise in hypertrophic cardiomyopathy. (1992) (1)
Sudden Death Risk in Patients With Hypertrophic Cardiomyopathy Prognostic Value of Quantitative Contrast-Enhanced Cardiovascular Magnetic Resonance (2014) (1)
Implantable Cardioverter-Defibrillators in Hypertrophic Cardiomyopathy (2020) (1)
Support and Advocacy Groups (2006) (1)
Long-Term Clinical Effects of Verapamil in Patients with Hypertrophic Cardiomyopathy* (1982) (1)
Stress cardiomyopathy. (2007) (1)
Left atrial-to-right atrial shunt without atrial septal defect or precordial murmur. Pulmonary varix and hypertrophic cardiomyopathy. (1982) (1)
Cardiovascular abnormalities in the athlete: recommendations regarding eligibility for competition. Task force III: Hypertrophic cardiomyopathy, other myopericardial diseases and mitral valve prolapse. (1985) (1)
Personalized Treatment Strategies Effective in Hypertrophic Cardiomyopathy Do Not Rely on Genomics in 2022: A Different Tale of Precision Medicine. (2022) (1)
Expanding Pathobiological Mechanisms in Hypertrophic Cardiomyopathy to Explain Heterogeneity: JACC Review Topic of the Week (2019) (1)
Diastolic prolapse of the pulmonary valve with regurgitation. (1997) (1)
Cardiovascular Diseases That Have Emerged From the Darkness (2021) (1)
Characterization of patients with massive hypertrophic cardiomyopathy using contrast-enhanced magnetic resonance imaging: does contrast provide additional information? (2012) (1)
Pathophysiology of asymmetric septal hypertrophy. (1977) (1)
Participation in Recreational Sports for Young Patients with Genetic Cardiovascular Diseases (2010) (1)
The Genetics and Semantics of Hypertrophic Cardiomyopathy (1978) (1)
PREVALENCE, CLINICAL PROFILE, AND OUTCOME OF CARDIORENAL SYNDROME IN SYMPTOMATIC PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY (2019) (1)
Precordial thumb ineffective in terminating ventricular fibrillation initiated by chest wall impact (commotio cordis) (2005) (1)
Sudden infant death syndrome (SIDS). Echocardiographic studies in relatives of infants with SIDS (1977) (1)
Permanent Pacing in Patients with Hypertrophic Cardiomyopathy (1999) (1)
Abstract 16578: Sudden Death is Less Common in Young Competitive Athletes Than in Non-athletes: But We Systematically Screen Only Athletes (2015) (1)
052 - Heart Transplantation for Hypertrophic Cardiomyopathy: The Tufts Experience (2017) (1)
Recommendations for use of laboratory studies for pediatric patients with suspected or proven heart disease. A statement of the Committee on Congenital Cardiac Defects of the Council on Cardiovascular Disease in the Young of the American Heart Association. (1986) (1)
Ultrastructural features of cardiac muscle cells in left ventricular myocardium of patients with chronic aortic valvular disease (1974) (1)
UNDER-RECOGNIZED CAUSES OF SUDDEN DEATH IN YOUNG ATHLETES: MYOCARDITIS AND MITRAL VALVE PROLAPSE (2018) (1)
Defibrillation threshold testing in hypertrophic cardiomyopathy: As SIMPLE as possible but not simpler. (2017) (1)
ATRIAL FIBRILLATION IS ASSOCIATED WITH LOW CARDIOVASCULAR MORTALITY IN HYPERTROPHIC CARDIOMYOPATHY (2016) (1)
[Atrial fibrillation in hypertrophic cardiomyopathy: determinants, clinical course and management]. (2009) (1)
Regression and remodeling of left ventricular hypertrophy with aging in hypertrophic cardiomyopathy (1998) (1)
Response to Letter Regarding Article, “Hypertrophic Cardiomyopathy Is Predominantly a Disease of Left Ventricular Outflow Tract Obstruction” (2007) (1)
Causes of Sudden Death During the Triathlon—Reply (2010) (1)
Role of Implantable Cardioverter Defibrillators in the Treatment of Hypertrophic Cardiomyopathy (2005) (1)
Abstract 14647: Stress Echocardiography Predicts Heart Failure Progression and Alters Management Strategies in Patients with Hypertrophic Cardiomyopathy (2014) (1)
233 Evidence that post-contrast delayed enhancement identified by cardiovascular magnetic resonance is an arrhythmogenic substrate in hypertrophic cardiomyopathy (2008) (1)
THE IMPACT OF ADVANCED THERAPIES IN IMPROVING SURVIVAL TO HEART TRANSPLANT IN HYPERTROPHIC CARDIOMYOPATHY (2018) (1)
RECURRENT TAKOTSUBO SYNDROME: FREQUENCY, PATIENT PROFILE, AND OUTCOMES (2018) (1)
Abstracts (2013) (1)
Left ventricular end diastolic pressure, suspected underlying hypertrophic cardiomyopathy, and takotsubo syndrome – reply. (2014) (1)
Sudden cardiac death caused by innocent chest wall blows. (2005) (1)
"Speckled" ventricular septum in hypertrophic cardiomyopathy revisited after 30 years. (2011) (1)
Summary of Presentations and Discussions of Hypertrophic Cardiomyopathy at the 2018 Boston International Summit VI Including Consensus, Controversies, and Unmet Needs. (2018) (1)
Relation Between Extent of Left Ventricular Hypertrophy Hypertrophic Cardiomyopathy and Age in (2016) (1)
[Prevention of sudden death in hypertrophic cardiomyopathy (HCM ): implanted defibrillators in HCM]. (2009) (1)
Abstract 13943: Hypertrophic Cardiomyopathy with Left Ventricular Apical Aneurysm Represents a High-Risk Subgroup Necessitating Aggressive Preventive Therapy: A Long-term Follow-Up Study (2014) (1)
Emergency Treatment for Commotio Cordis—Reply (2002) (1)
Altered Intercellular Communication and Extracellular Matrix Signaling as a Disease Mechanism in Human Hypertrophic Cardiomyopathy (2021) (1)
INCIDENCE OF CARDIOVASCULAR SUDDEN DEATHS IN MINNESOTA HIGH SCHOOL COMPETITIVE ATHLETES: IMPACT ON CONSIDERATIONS FOR NATIONAL 12–LEAD ECG PREPARTICIPATION SCREENING (2013) (1)
Abstract 13120: Hypertrophic Cardiomyopathy with Longevity into the Tenth Decade of Life (2011) (1)
Images in cardiovascular medicine. Cardiovascular disease in ankylosing (Marie-Strümpell) spondylitis. (1997) (1)
Author Correction: Individualized interactomes for network-based precision medicine in hypertrophic cardiomyopathy with implications for other clinical pathophenotypes (2022) (1)
1032-121 Utility of B-type natriuretic peptide assay in the assessment of symptomatic state in hypertrophic cardiomyopathy (2004) (1)
Images in cardiovascular medicine. Hypertrophic cardiomyopathy with apical aneurysm. (2004) (1)
Cardiology Clinics—The Athleteʼs Heart (1995) (1)
Defining Commotio Cordis. (2019) (1)
When Does HCM Develop?: HCM in Infants and Children (2006) (0)
Mutations in human cardiac myosin binding protein C cause late-onset familiar hypertrophic cardiomyopathy (1997) (0)
Abstract 8115: Circadian Rhythm Pattern of Events in Tako-tsubo Cardiomyopathy (2011) (0)
Abstract 14340: Premonitory Supraventricular Arrhythmas Triggering Ventricular Arrhythmias in Patients with Hypertrophic Cardiomyopathy and ICDs: Implications for Preventive Therapy (2012) (0)
Sudden Cardiac Death and Preparticipation Screening in Young Athletes: 330 4:10 PM - 4:40 PM (2005) (0)
Abstract 647: Important Role of Positive Family History of Sudden Death in Risk Stratification and Prevention of Death with the Implantable Defibrillator in Patients with Hypertrophic Cardiomyopathy (2008) (0)
General Outlook For Patients with HCM (2006) (0)
Efficacy of Operation for Obstructive Hypertrophic Cardiomyopathy: A 20-Year Experience with Ventricular Septal Myotomy and Myectomy (1982) (0)
Cardiovascular Abnormalities in Competitive Athletes: 2007 Update : Recommendations and Considerations Related to Preparticipation Screening for (2012) (0)
Hypertrophic cardiomyopathy in the “real world”; prevalence, demographics and clinical expression in an unselected and unreferred hospital-based patient population (1998) (0)
Is the 12-lead electrocardiogram of value in the prognostic assessment of patients with hypertrophic cardiomyopathy? (2010) (0)
Cats Have Nine Lives but This Hypertrophic Cardiomyopathy Patient Has Had Ten (So Far). (2022) (0)
Electrocardiographic clues in diagnosing syncope. (1971) (0)
Polymorphic regurgitation jets in a flail mitral valve. (1998) (0)
ECHOCARDIOGRAPHIC ABNORMALITIES IN OSTEOGENESIS IMPERFECTA (OI) (1984) (0)
Hypertrophic Cardiomyopathy Clinical Profile of Stroke in 900 Patients With Hypertrophic Cardiomyopathy (2001) (0)
P3167Extra long term follow up of the original tuscany cohort of patients with hypertrophic cardiomyopathy (2018) (0)
Chapter 64 – Ventricular Arrhythmias in Hypertrophic Cardiomyopathy (2004) (0)
Abstract 12673: How Low is Low Risk in Hypertrophic Cardiomyopathy? Sudden Death in Patients Without Conventional Risk Factors (2011) (0)
Risks of the Athletic Field Revisited: Report of Unusual Occurrences of Cardiac Arrest and Sudden Death in Professional Soccer Players. (2022) (0)
2027 Accuracy and reproducibility of quantifying myocardial fibrosis in hypertrophic cardiomyopathy using delayed enhancement cardiovascular magnetic resonance thresholding techniques (2008) (0)
Spectrum of regurgitation jets in mitral valve prolapse. (1995) (0)
Society for Cardiovascular Pathology Symposium 2009 Can sudden cardiac death be prevented (2010) (0)
Characterization of tissue heterogeneity by contrast-enhanced cardiovascular magnetic resonance imaging is a powerful predictor of ventricular tachyarrhythmias on ambulatory holter ECG in hypertrophic cardiomyopathy (2009) (0)
Book ReviewTwo-Dimensional Echocardiographic Atlas, Volume I: Congenital heart disease (1988) (0)
Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy : A Randomized , Assessment of Permanent Dual-Chamber Pacing as a Treatment for Drug-Refractory (1999) (0)
Abstract 10805: Does the 12-lead ECG Have Limitations in Detecting Hypertrophic Cardiomyopathy in the Pre-Participation Screening of Athletes? (2011) (0)
Possible sources of cryptogenic cerebral emboli as revealed by transesophageal echocardiography. (1996) (0)
Reflections on Six Decades of Hypertrophic Cardiomyopathy From Eugene Braunwald. (2022) (0)
Treatment of Hypertrophic Cardiomyopathy (2011) (0)
Abstract 9782: Sudden Death in U.S. College Athletes: Incidence, Causes, and Implications for Preparticipation Screening (2013) (0)
Abnormalities Eligibility and Disqualification of Competitive Athletes With Cardiovascular Recommendations Revisited: A Comparison of U.S. and European Criteria for (2008) (0)
Neurogenic Orthostatic Hypotension (2008) (0)
Analysis of dual-chamber pacing as a treatment for refractory limiting symptoms in patients with obstructive hypertrophic cardiomyopathy (2000) (0)
Survival andfunctional results after valve replacement foraortic regurgitation from1976to 1983: impact ofpreoperative left ventricular function (2011) (0)
Long-term prognosis and symptomatic status of patients after operation for IHSS (1978) (0)
Implantable defibrillator for prevention of sudden death in patients with hypertrophic cardiomyopathy (2001) (0)
Abstract 2592: Clinical Events and MSCTA Anatomy in Anomalous Coronary Artery Arising from the Opposite Coronary Sinus (AOCOS): Relationship of the Pulmonary Valve, Slit-like Orifice, and Arterial Course (2007) (0)
AORTIC DISEASE Reversal of left ventricular dysfunction after aortic valve replacement for chronic aortic regurgitation : influence of duration of preoperative left ventricular dysfunction (2005) (0)
Jeffrey Michael Isner, MD (1947 to 2001) (2002) (0)
Alcohol Ablation or Ventricular Septal Myotomy/Myectomy for Severe Obstructive Hypertrophic Cardiomyopathy? (2020) (0)
General Lifestyle Advice (2006) (0)
Aldosterone targets Raptor to promote pulmonary smooth muscle cell proliferation and modulate pulmonary arterial hypertension (2013) (0)
Erratum to 'Defining Commotio Cordis': The American Journal of Cardiology Volume 124, Issue 10, 15 November 2019, Pages 1649-1650. (2023) (0)
Hypertrophic Cardiomyopathy Association Membership Application (2006) (0)
Methods for Distinguishing Athlete’s Heart from Structural Heart Disease, with Emphasis on Hypertrophic Cardiomyopathy (1997) (0)
Reply: To PMID 24630786. (2014) (0)
Hypertrophic Cardiomyopat'Iy Characterized by Marked Hypertrophy Of the Posterior Left Ventricular Free Wall : Significance and Clinical Implications (2010) (0)
Natural history of middle-aged asymptomatic patients with hypertrophic cardiomyopathy (1990) (0)
Boxer Dogs : A New Animal Model of Human Disease Arrhythmogenic Right Ventricular Cardiomyopathy Causing Sudden Cardiac Death in (2004) (0)
Super Recurrence of Takotsubo Syndrome: Clinical Characteristics and Late Cardiac Outcomes. (2023) (0)
What Research is Being Conducted (2006) (0)
Reply: Nonobstructive Hypertrophic Cardiomyopathy: Low Mortality but Not Always Benign. (2016) (0)
Hypertrophic Cardiomyopathy Morphology and Significance of the Left Ventricular Collagen Network in Young Patients With Hypertrophic Cardiomyopathy and Sudden Cardiac Death (2016) (0)
Abstract 10190: Double or Compound Sarcomere Mutations Associated with Sudden Death Risk in Hypertrophic Cardiomyopathy in the Absence of Conventional Risk Factors (2011) (0)
Focal LGE and Outcome in HCM JACC Cardiovascular Imaging 1 CLINICAL SIGNIFICANCE OF LATE GADOLINIUM ENHANCEMENT AT RIGHT VENTRICULAR ATTACHMENT TO VENTRICULAR SEPTUM IN HYPERTROPHIC CARDIOMYOPATHY Running title: Focal LGE and Outcome in HCM (2014) (0)
FATALITIES IN UNITED STATES TRIATHLONS: AN EXPANDED PROFILE (2016) (0)
What are the Symptoms of HCM (2006) (0)
How is HCM Diagnosed and What Tests are Used (2006) (0)
Response to Reader's Comment Titled: “Is the Italian Model Really A More Effective Preparticipation Cardiovascular Screening Strategy for Competitive Athletes?” (2010) (0)
Lifetime mortality associated with hypertrophic cardiomyopathy: 28-year outcome of an historical cohort (2020) (0)
Cardiovascular Screening of High School Athletes—Reply (1999) (0)
GLOBAL LONGITUDINAL STRAIN PREDICTS PROGRESSIVE HEART FAILURE IN NONOBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (2020) (0)
Is preparticipation screening for cardiovascular disease adequate in United States high schools (1998) (0)
Hypertrophic Cardiomyopathy and Coronary Arteries (2002) (0)
Abstract 16551: Pathways of Prognosis and Effective Treatment Interventions in Hypertrophic Cardiomyopathy (2015) (0)
Obstructive Hypertrophic Cardiomyopathy (2005) (0)
Dr. Howard Burchell Remembered (2010) (0)
932-86 Importance of Collagen in Myocardial Ischemia and Remodeling of Abnormal Intramural Coronary Arteries (“Small Vessel Disease”) in Young Patients with Hypertrophic Cardiomyopathy and Sudden Cardiac Death (1995) (0)
Primary prevention of sudden cardiac death in hypertrophic cardiomyopathy (2018) (0)
What is Hypertrophic Cardiomyopathy (HCM) (2006) (0)
Abstract 4876: LAMP2 Cardiomyopathy is a Particularly Adverse Phenocopy of Sarcomeric Hypertrophic Cardiomyopathy (2008) (0)
Review Article Commotio Cordis (2007) (0)
What is the Cause of HCM (2006) (0)
Natural History of Hypertrophic Cardiomyopathy: A Benign or Progressive Disorder? (1997) (0)
Is surgical myectomy challenged by emergence of novel drug therapy with mavacamten? (2022) (0)
Editorial commentary: Hold your horses (and mice, rats, and cats): How relevant really are animal models of hypertrophic cardiomyopathy? (2019) (0)
IDENTIFICATION OF CARDIAC AMYLOIDOSIS AMONG A COHORT OF HYPERTROPHIC CARDIOMYOPATHY PATIENTS (2019) (0)
Glycogen Storage Diseases and Cardiomyopathy (2010) (0)
A biological model of commotio cordis: sudden death from low energy cheat wall impact (1998) (0)
Upper limits and clinical significance of left atrium dilatation in trained athletes (2003) (0)
Hypertrophic Cardiomyopathy 2003 (2012) (0)
The 34 Most Frequently Asked Questions by Patients About HCM, as Addressed to the HCMA (2006) (0)
Hypertrophic cardiomyopathy (1997) (0)
IS IDIOPATHIC LEFT BUNDLE BRANCH BLOCK IN HYPERTROPHIC CARDIOMYOPATHY A MARKER FOR ADVERSE OUTCOMES? (2023) (0)
USE OF ECG DEEP-LEARNING TO IDENTIFY HYPERTROPHIC CARDIOMYOPATHY PATIENTS WITH HIGH-RISK FEATURES (2023) (0)
Barry Joel Maron, MD: a conversation with the Editor. Interview by William Clifford Roberts. (2007) (0)
Hypertrophic Cardiomyopathy Association (2014) (0)
Determinants of the “athlete heart” defined in a population of 947 highly trained flite athletes (1991) (0)
How common is hypertrophic cardiomyopathy… really?: Disease prevalence revisited 27 years after CARDIA. (2023) (0)
Management of patients with hypertrophic cardiomyopathy (1991) (0)
HYPERTROPHIC CARDIOMYOPATHY IN ICELAND IS CHARACTERIZED BY LOW EVENT RATE CLINICAL COURSE AND MYBPC3 FOUNDER MUTATION (2014) (0)
criminal consequences of commotio cordis: Reply (2002) (0)
Reply: To PMID 25759101. (2015) (0)
2048 The hypertrophic cardiomyopathy phenotype revisited with cardiovasculara magnetic resonance (2008) (0)
DIAGNOSIS OF CYANOTIC CONGENITAL HEART MALFORMATIONS IN INFANTS BY REAL-TIME, TWO-DIMENSIONAL ECHOCARDIOGRAPHY (1974) (0)
Group of the National Heart, Lung, and Blood Institute Research Priorities in Hypertrophic Cardiomyopathy : Report of a Working (2011) (0)
Abstract 15961: Multicenter Prospective Prevention of Sudden Death in High Risk Patients Utilizing Enhanced ACC/AHA Risk Model (2020) (0)
Morphologic determinants of the mechanisms of subaortic obstruction in hypertrophic cardiomyopathy (1991) (0)
A Heart Failure Story. (2021) (0)
Late-onset primary LVHHCM versus cardiac fabry variant: reply (2002) (0)
Emergency treatment for commotio cordis. Authors' reply (2002) (0)
Mitral valve prolapse in hypertrophic cardiomyopathy significance in a subset of patients with unique mitral valve motion (1988) (0)
Circadian variation in the occurrence of sudden death in hypertrophic cardiomyopathy (1991) (0)
Sudden Death Due to Chest Blows (Commotio Cordis) (2007) (0)
SICKLE CELL TRAIT CAUSING SUDDEN DEATH IN COMPETITIVE ATHLETES: OBSERVATIONS FROM THE 30-YEAR U.S. NATIONAL SUDDEN DEATH IN YOUNG ATHLETES REGISTRY (2011) (0)
Other Investigations That May be Useful (2006) (0)
Reply: Atrial Fibrillation in Hypertrophic Cardiomyopathy. (2018) (0)
The use of verapamil in the treatment of hypertrophic cardiomyopathy (1987) (0)
1032-125 Electrocardiographic pattern of giant negative T wave in hypertrophic cardiomyopathy: Is it a specific feature of “Apical” hypertrophic cardiomyopathy? (2004) (0)
Dr. Douglas E. Wigle. (2015) (0)
Practice Guidelines Consensus Documents and the European Society of Cardiology Committee for (2007) (0)
Identification of Transthyretin Cardiac Amyloidosis Among Patients Previously Diagnosed With Hypertrophic Cardiomyopathy. (2022) (0)
Special Report Research Priorities in Hypertrophic Cardiomyopathy Report of a Working Group of the National Heart, Lung, and Blood Institute Genetic Cause (2010) (0)
Hypertrophic and Dilated Cardiomyopathy Long-Term Effects of Surgical Septal Myectomy on Survival in Patients With Obstructive Hypertrophic Cardiomyopathy (2005) (0)
Historical Perspective, Mechanism, and Clinical Significance of Left Ventricular Outflow Tract Obstruction in Hypertrophic Cardiomyopathy (2007) (0)
Is a Cure Available (2006) (0)
Perianesthetic management of hypertrophic cardiomyopathy. Authors' reply (2006) (0)
Clinical profile of peripheral embolization in patients with hypertrophic cardiomyopathy: a cooperative United States and Italy study (1998) (0)
Authors' reply: takotsubo cardiomyopathy. (2013) (0)
Risk Stratification and the Implantable Defibrillator for the Prevention of Sudden Death in Hypertrophic Cardiomyopathy (2009) (0)
FEMALE GENDER IS ASSOCIATED WITH MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY (2012) (0)
86 – Ventricular Arrhythmias in Hypertrophic Cardiomyopathy: Sudden Death, Risk Stratification, and Prevention With Implantable Defibrillators (2018) (0)
Clinical implications for molecular genetics of cardiomyopathy (2005) (0)
for Young Patients With Genetic Cardiovascular Diseases Recommendations for Physical Activity and Recreational Sports Participation (2007) (0)
Abstract 14342: The Underappreciated Occurrence of Discrete Subaortic Membranes Producing LV Outflow Obstruction in Patients With Hypertrophic Cardiomyopathy (2016) (0)
Jeff Zucker Says Hypertrophic Cardiomyopathy is a Curable Disease: A Patient's Perspective. (2022) (0)
Images in cardiovascular medicine. Leaflet-dependent spectrum of regurgitant jet in mitral valve prolapse. (1998) (0)
Abstract 4667: Mechanisms of Life Threatening Ventricular Tachyarrhythmias in Patients with Hypertrophic Cardiomyopathy: Implication for Prevention of Sudden Death (2008) (0)
Abstract 17402: Single Nuclei RNA-sequencing of Human Hypertrophic Cardiomyopathy Myectomy Samples Reveals Common Novel Mechanisms of Pathogenesis and Potential Therapeutic Targets Regardless of Genotype (2020) (0)
Response to Letter Regarding Article, "Clinical Impact of Contemporary Cardiovascular Magnetic Resonance Imaging in Hypertrophic Cardiomyopathy". (2016) (0)
Prevalence of Fabry Disease in a High Risk U.S. Cohort with Hypertophic Cardiomyopathy and Other Cardiac Diagnoses (2012) (0)
CARDIOVASCULAR SCREENING OF HIGH SCHOOL ATHLETES. AUTHORS' REPLIES (1999) (0)
Left ventricular filling abnormalities in hypertrophic cardiomyopathy (2006) (0)
Reply: Commotio Cordis is an Athlete (2005) (0)
Stress-induced cardiomyopathy Stress-induced takotsubo cardiomyopathy Stress-induced apical ballooning syndrome Stress-related left ventricular dysfunction Stress-related cardiomyopathy Stress-related cardiomyopathy syndrome Stress takotsubo cardiomyopathy Emotional stress-induced ampulla cardiomyop (2011) (0)
Abstract 3097: Significance of Delayed Enhancement with Contrast Enhanced Cardiovascular Magnetic Resonance in Hypertrophic Cardiomyopathy (2007) (0)
Abstract 14941: Left Ventricular Apico-Basal Muscle Bundle Identified by Cardiovascular Magnetic Resonance Imaging in Patients with Hypertrophic Cardiomyopathy: Implications for Diagnosis and Management (2012) (0)
Two husbands--one disease: the broad clinical spectrum of hypertrophic cardiomyopathy. (2002) (0)
Treatments for HCM (2006) (0)
Measurement of infarct size by cardiac MRI Cardiac CT – do we need it ? Does myocardial deformation imaging improve the interpretation of stress echocardiography 3 D echocardiography in clinical practice (2013) (0)
Concealed Retrograde Conduction in AV Block (2005) (0)
Fabry Disease in Families With Hypertrophic Cardiomyopathy (2017) (0)
Gender and Race (2006) (0)
Utility of Intraoperative Echocardiography in Planning Surgical Strategy in Obstructive Hypertrophic Cardiomyopathy (1990) (0)
Response to Elliott and McKenna (2009) (0)
2055 Clinical profile and significance of delayed enhancement in hypertrophic cardiomyopathy (2008) (0)
Erratum to "Hypertrophic Cardiomyopathy: Is a 'Cure' Coming … Or Is It Already Here?": American Journal of Medicine, 133 (2020):8:886-888. (2021) (0)
Abstract 19706: Increasing Survival and Decreasing Sudden Death Rate from Commotio Cordis (2012) (0)
917 IS DISPROPORTIONATE VENTRICULAR SEPTAL THICKENING A RELIABLE MARKER OF HYPERTROPHIC CARDIOMYOPATHY IN INFANTS? (1978) (0)
catechol-Left Ventricular End Diastolic Pressure, Suspected Underlying Hypertrophic Cardiomyopathy, and Takotsubo Syndrome (2014) (0)
LEFT VENTRICULAR HYPERTROPHY IN ATHLETES: THE “GRAY-ZONE” REVISITED (2014) (0)
ong-Term Effects of Surgical Septal yectomy on Survival in Patients With bstructive Hypertrophic Cardiomyopathy (2005) (0)
Key HCM References (2006) (0)
AORTIC REGURGITATION Cardiovascular involvement in osteogenesis imperfecta (2005) (0)
Abstract 17341: Obesity is Associated With Progressive Heart Failure in Hypertrophic Cardiomyopathy (2020) (0)
Global Dissemination and Implementation of Contemporary Management Principles for Hypertrophic Cardiomyopathy and Role of the International HCM Summit. (2022) (0)
Evidence against the efficacy of current chest wall protection for sudden death due to precordial blows (commotio cordis) (2002) (0)
Relation Between Extent of Left Ventricular Hypertrophy a Diastolic Filling Abnormalities i Y ertr is (2016) (0)
Complications of HCM (2006) (0)
Comparison of hypertrophic cardiomyopathy in human, cat and dog. (1990) (0)
Experience with cardioverter-defibrillator implantation in high-risk patients with hypertrophic cardiomyopathy (2005) (0)
Sudden cardiac death in genetic heart diseases and the promise of prevention. (2010) (0)
Reply: To PMID 23245842. (2013) (0)
MANAGING ELITE ATHLETES WITH CARDIOVASCULAR ABNORMALITIES: INSIGHTS FROM THE 30-YEAR ITALIAN EXPERIENCE (1998) (0)
Addition of Spironolactone to Ambrisentan May Be a Novel Treatment Strategy to Improve Outcome in Patients with PAH (2013) (0)
2049 Improved detection of myocardial fibrosis using high-resolution, late gadolinium-enhanced cardiovascular magnetic resonance in patients with hypertrophic cardiomyopathy (2008) (0)
Electrophysiolog ic Abnormalities inPatients WithHypertrophic Cardiomyopathy A Consecutive Analysis in155Patients (1989) (0)
cardiomyopathydeath and prevention in hypertrophic Contemporary considerations for risk stratification (2008) (0)
Concerns About the HCM Risk-Kids Study. (2020) (0)
What About Having Children?: Pregnancy and Delivery (2006) (0)
DIASTOLIC FUNCTION IN MYOSIN-BINDING PROTEIN C FOUNDER MUTATION CARRIERS WITH AND WITHOUT CLINICAL EVIDENCE OF HYPERTROPHIC CARDIOMYOPATHY (2019) (0)
OUTCOMES OF SPORTS PARTICIPATION FOR PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY AND IMPLANTABLE CARDIOVERTER-DEFIBRILLATORS: DATA FROM THE ICD SPORTS REGISTRY (2020) (0)
A multicenter study of the safety and efficacy of disopyramide for treating symptomatic obstructive hypertrophic cardiomyopathy (2003) (0)
Controversy in 2014 Surgical Septal Myectomy Versus Alcohol Septal Ablation: Assessing the Status of the (2014) (0)
Routine Medical Care (2006) (0)
Dr. Gunnar Thor Gunnarsson and hypertrophic cardiomyopathy: what "giving back" means. (2010) (0)
145Clinical course and significance of hypertrophic cardiomyopathy without left ventricular hypertrophy (2018) (0)
DOPPLER TISSUE IMAGING PREDICTS PROGRESSIVE HEART FAILURE PROGNOSIS IN HYPERTROPHIC CARDIOMYOPATHY (2015) (0)
The alpha-tropomyosin Asp175Asn missense mutation causes a benign form of hypertrophic cardiomyopathy (1996) (0)
Lack of Phenotypic Differences by Cardiovascular Magnetic Resonance Imaging in MYH 7 ( βMyosin βMyosin βMyosin Heavy Chain )Versus )Versus )Versus MYBPC 3 ( MyosinBinding MyosinBinding MyosinBinding Protein C )Related )Related )Related Hypertrophic Cardiomyopathy (2017) (0)
Abstract 3960: Commercially Available Sports Equipment Do Not Protect Young Competitive Athletes Against Commotio Cordis-Related Sudden Death (2006) (0)
The Reply. (2017) (0)
Special Considerations: Athletes and Sports Activities (2006) (0)
Characterization of myosin from patients with asymmetric septal hypertrophy. (1976) (0)
Reply: To PMID 22809753. (2013) (0)
Prognosis of Apical Hypertrophic Cardiomyopathy—Reply (2007) (0)
Abstract 18019: Successful Surgical Management of Severely Symptomatic Hypertrophic Cardiomyopathy Patients With Minimal Septal Hypertrophy (2014) (0)
SUDDEN DEATH IN YOUNG COMPETITIVE ATHLETES DUE TO AORTIC VALVE AND AORTIC DISEASE (2013) (0)
Myocarditis in hypertrophic cardiomyopathy. (2007) (0)
How Common is HCM (2006) (0)
Patients With Hypertrophic Cardiomyopathy: A Comprehensive Mutational Analysis of Troponin T, Troponin I, Alpha Tropomyosin, and Cardiac Actin (2003) (0)
The occurrence of alpha-glycogen in humans. (1974) (0)
that it contained the underlying study of his first catheter- based treatment of HOCM. (2010) (0)
“SILENT” ATRIAL FIBRILLATION BURDEN IN PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY (2015) (0)
Verapamil new approach to the treatment of patients with hypertrophic cardio myopathy (1979) (0)
Phenotypic Expression and Clinical Course of Hypertrophic Cardiomyopathy (2007) (0)
OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY WITH MILD PHENOTYPE: A NOVEL SUBGROUP OF PATIENTS AMENABLE TO SURGICAL MYECTOMY (2018) (0)
Ventricular and Supraventricular Tachyarrhythmias Associated with Hypertrophic Cardiomyopathy (2012) (0)
The Reply. (2023) (0)
Commentary: Severe Aortic Stenosis in a Professional Football Player (2003) (0)
Acquired coarctation of the descending thoracic aorta. (1996) (0)
IMPACT OF OBESITY ON THE PHENOTYPE AND CLINICAL COURSE OF HYPERTROPHIC CARDIOMYOPATHY (2012) (0)
Prevalence and clinical significance of isolated increase of QRS voltages on 12-lead electrocardiogram of patients with hypertrophic cardiomyopathy and trained athletes (2008) (0)
Prognostic significance of morphologic abnormalities in hypertrophic cardiomyopathy (2006) (0)
PREVALENCE AND CLINICAL FEATURES OF NONRESPONDERS TO SURGICAL MYECTOMY WITH OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (2018) (0)
Heart Structure in HCM (2006) (0)
Risk for sudden cardiac death during the marathon (1994) (0)
MASSIVE LV HYPERTROPHY IN HYPERTROPHIC CARDIOMYOPATHY IS A HIGH-RISK SUBGROUP, BUT IS ASSOCIATED WITH FAVORABLE OUTCOME WITH CONTEMPORARY TREATMENTS (2018) (0)
Editorial note Living with the septal to free wall thickness ratio (1983) (0)
A novel patient-patient network medicine approach to refine hypertrophic cardiomyopathy subgrouping: implications for risk stratification. (2023) (0)
Merck's Careful Study of Vioxx. Authors' reply (2008) (0)
Fixed diffuse left ventricular outflow obstruction: a diagnostic and therapeutic dilemma☆ (1976) (0)
Late gadolinium enhancement is compatible with advanced age in hypertrophic cardiomyopathy: implications for risk stratification of sudden death (2012) (0)
301. INCIDENCE OF ADVERSE EVENTS DURING CARDIAC MAGNETIC RESONANCE IMAGING IN CONGENITAL HEART DISEASE (2006) (0)
ELECTROCARDIOGRAPHIC FINDINGS IN MYOSIN-BINDING PROTEIN C FOUNDER MUTATION CARRIERS (2019) (0)
Flail mitral valve and sudden cardiac death. (2000) (0)
Chapter 29 – Arrhythmias Associated with Hypertrophic Cardiomyopathy (2005) (0)
Abstract 4683: Risk Stratification in Hypertrophic Cardiomyopathy: Evidence that Syncope is a Marker for Sudden Death (2008) (0)
Natural history of hypertrophic cardiomyopathy during childhood revisited in an unselected community-based population (1996) (0)
LQTS and SIDS linkage: clarifying the record. (2005) (0)
Abstract 1712: Deep Myocardial Bridging is a Risk Factor for Sudden Death in Hypertrophic Cardiomyopathy (2006) (0)
Abstract 3092: Risk Associated with Sports Competition: Is Lacrosse Really a Uniquely Dangerous Sport? (2008) (0)
Safety baseballs reduce ventricular fibrillation and EKG changes in a biological model of commotio cordis, sudden death from low energy chest wall impact (1998) (0)
Pathophysiologic mechanisms responsible for the clinical spectrum of hypertrophic cardiomyopathy (1985) (0)
ANTIARRHYTHMIC MEDICATIONS FOR ATRIAL FIBRILLATION APPEAR REASONABLY SAFE IN HYPERTROPHIC CARDIOMYOPATHY (2017) (0)
Evidence that left ventricular outflow tract obstruction is a predictor of outcome in patients with hypertrophic cadiomyopathy (2003) (0)
Echocardiographic assessment of the left ventricle following myotomy and myectomy for idiopathic hypertrophic subaortic stenosis (IHSS) (1978) (0)
magnitude and significance athlete's heart: a clinical problem of increasing Distinguishing hypertrophic cardiomyopathy from (2007) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Barry Joel Maron?

Barry Joel Maron is affiliated with the following schools: